




(86) Date de dépôt PCT/PCT Filing Date: 2011/07/21
(87) Date publication PCT/PCT Publication Date: 2012/01/26
(45) Date de délivrance/Issue Date: 2020/05/12
(85) Entrée phase nationale/National Entry: 2013/01/14
(86) N° demande PCT/PCT Application No.: US 2011/044902
(87) N° publication PCT/PCT Publication No.: 2012/012667
(30) Priorités/Priorities: 2010/07/21 (US61/400,009);
2010/10/06 (US61/404,685)

(51) Cl.Int./Int.Cl. C07K 7/06 (2006.01),
A61K 35/14 (2015.01), A61P 37/06 (2006.01),
C07K 14/47 (2006.01), C07K 14/705 (2006.01),
C07K 14/725 (2006.01), C07K 14/74 (2006.01),
C07K 19/00 (2006.01), C12N 15/00 (2006.01),
C12N 15/11 (2006.01), C12N 15/55 (2006.01),
C12N 15/62 (2006.01), ...

(72) Inventeurs/Inventors:
COLLINGWOOD, TREVOR, US;
COOPER, LAURENCE J.N., US;
GREGORY, PHILIP D., US;
HOLMES, MICHAEL C., US;
...

(73) Propriétaires/Owners:

(54) Titre : METHODES ET COMPOSITIONS POUR MODIFIER UN LOCUS HLA
(54) Title: METHODS AND COMPOSITIONS FOR MODIFICATION OF AN HLA LOCUS



(57) Abrégé/Abstract:

Disclosed herein are methods and compositions for modulating the expression of a HLA locus or for selectively deleting or manipulating a HLA locus or HLA regulator.

(51) Cl.Int./Int.Cl. (suite/continued) *C12N 5/10* (2006.01), *C12N 9/22* (2006.01), *C12N 9/96* (2006.01)

(72) Inventeurs(suite)/Inventors(continued): MILLER, JEFFREY C., US; REBAR, EDWARD J., US; REIK, ANDREAS, US; URNOV, FYODOR, US

(73) Propriétaires(suite)/Owners(continued): BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM, US; SANGAMO THERAPEUTICS, INC., US

(74) Agent: KIRBY EADES GALE BAKER

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
26 January 2012 (26.01.2012)(10) International Publication Number
WO 2012/012667 A3

(51) International Patent Classification:

C07K 14/00 (2006.01)

(21) International Application Number:

PCT/US2011/044902

(22) International Filing Date:

21 July 2011 (21.07.2011)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

| | | |
|------------|-----------------------------|----|
| 61/400,009 | 21 July 2010 (21.07.2010) | US |
| 61/404,685 | 6 October 2010 (06.10.2010) | US |

(71) **Applicants** (for all designated States except US): **SANGAMO BIOSCIENCES, INC.** [US/US]; Point Richmond Tech Center, 501 Canal Blvd., Suite A100, Richmond, California 94804 (US). **BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM** [US/US]; 1515 Holcombe Blvd., Houston, Texas 77030 (US).

(72) Inventors; and

(75) **Inventors/Applicants** (for US only): **COLLINGWOOD, Trevor** [NZ/US]; c/o Sangamo BioSciences, Inc., Point Richmond Tech Center, 501 Canal Blvd., Suite A100, Richmond, California 94804 (US). **COOPER, Laurence J.,N.** [US/US]; University Of Texas M.D. Anderson Cancer Center, 1515 Holcombe Blvd., Houston, Texas 77030


(US). **GREGORY, Philip D.** [GB/US]; Sangamo BioSciences, Inc., Point Richmond Tech Center, 501 Canal Blvd., Suite A100, Richmond, California 94804 (US). **HOLMES, Michael C.** [US/US]; Sangamo BioSciences, Inc., Point Richmond Tech Center, 501 Canal Blvd., Suite A100, Richmond, California 94804 (US). **MILLER, Jeffrey C.** [US/US]; Sangamo BioSciences, Inc., Point Richmond Tech Center, 501 Canal Blvd., Suite A100, Richmond, California 94804 (US). **REBAR, Edward J.** [US/US]; Sangamo BioSciences, Inc., Point Richmond Tech Center, 501 Canal Blvd., Suite A100, Richmond, California 94804 (US). **REIK, Andreas** [DE/US]; Sangamo BioSciences, Inc., Point Richmond Tech Center, 501 Canal Blvd., Suite A100, Richmond, California 94804 (US). **URNOV, Fyodor** [US/US]; Sangamo BioSciences, Inc., Point Richmond Tech Center, 501 Canal Blvd., Suite A100, Richmond, California 94804 (US).

(74) **Agents:** **PASTERNAK, Dahna S.** et al.; Robins & Pasternak LLP, 1731 Embarcadero Rd., Suite 230, Palo Alto, California 94303 (US).

(81) **Designated States** (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD,

[Continued on next page]

(54) Title: METHODS AND COMPOSITIONS FOR MODIFICATION OF A HLA LOCUS

**FIG. 1**

(57) **Abstract:** Disclosed herein are methods and compositions for modulating the expression of a HLA locus or for selectively deleting or manipulating a HLA locus or HLA regulator.

WO 2012/012667 A3



ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

(88) Date of publication of the international search report:

10 May 2012

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK,

**METHODS AND COMPOSITIONS FOR MODIFICATION OF AN HLA
LOCUS**

5

10 [0001]

[0002]

TECHNICAL FIELD

15 [0003] The present disclosure is in the fields of gene expression, genome engineering and gene therapy.

BACKGROUND

20 [0004] MHC antigens were first characterized as proteins that played a major role in transplantation reactions. Rejection is mediated by T cells reacting to the histocompatibility antigens on the surface of implanted tissues, and the largest group of these antigens is the major histocompatibility antigens (MHC). These proteins are expressed on the surface of all higher vertebrates and are called H-2 antigens in mice (for histocompatibility-2 antigens) and HLA antigens (for human leukocyte antigens) 25 in human cells.

30 [0005] The MHC proteins serve a vital role in T cell stimulation. Antigen presenting cells (often dendritic cells) display peptides that are the degradation products of foreign proteins on the cell surface on the MHC. In the presence of a co-stimulatory signal, the T cell becomes activated, and will act on a target cell that also displays that same peptide/MHC complex. For example, a stimulated T helper cell will target a macrophage displaying an antigen in conjunction with its MHC, or a cytotoxic T cell (CTL) will act on a virally infected cell displaying foreign viral peptides.

[0006] MHC proteins are of two classes, I and II. The class I MHC proteins are heterodimers of two proteins, the α chain, which is a transmembrane protein encoded by the MHC1 gene, and the β 2 microglobulin chain, which is a small extracellular protein that is encoded by a gene that does not lie within the MHC gene cluster. The α chain folds into three globular domains and when the β 2 microglobulin chain is associated, the globular structure complex is similar to an antibody complex. The foreign peptides are presented on the two most N-terminal domains which are also the most variable. Class II MHC proteins are also heterodimers, but the heterodimers comprise two transmembrane proteins encoded by genes within the MHC complex. The class I MHC:antigen complex interacts with cytotoxic T cells while the class II MHC presents antigens to helper T cells. In addition, class I MHC proteins tend to be expressed in nearly all nucleated cells and platelets (and red blood cells in mice) while class II MHC protein are more selectively expressed. Typically, class II MHC proteins are expressed on B cells, some macrophage and monocytes, Langerhans cells, and dendritic cells.

[0007] The class I HLA gene cluster in humans comprises three major loci, B, C and A, as well as several minor loci. The class II HLA cluster also comprises three major loci, DP, DQ and DR, and both the class I and class II gene clusters are polymorphic, in that there are several different alleles of both the class I and II genes within the population. There are also several accessory proteins that play a role in HLA functioning as well. The Tap1 and Tap2 subunits are parts of the TAP transporter complex that is essential in loading peptide antigens on to the class I HLA complexes, and the LMP2 and LMP7 proteosome subunits play roles in the proteolytic degradation of antigens into peptides for display on the HLA. Reduction in LMP7 has been shown to reduce the amount of MHC class I at the cell surface, perhaps through a lack of stabilization (see Fehling *et al* (1999) *Science* 265:1234-1237). In addition to TAP and LMP, there is the tapasin gene, whose product forms a bridge between the TAP complex and the HLA class I chains and enhances peptide loading. Reduction in tapasin results in cells with impaired MHC class I assembly, reduced cell surface expression of the MHC class I and impaired immune responses (see Grandea *et al* (2000) *Immunity* vol 13:213-222 and Garbi *et al* (2000) *Nat Immunol* 1:234-238).

[0008] Regulation of class I expression is generally at the transcriptional level, and several stimuli such as viral infection etc. can cause a change in transcription.

The class I genes are down-regulated in some specific tissues, and the source of this down-regulation seems to be within the promoter and 3' intergenic sequences (see Cohen *et al* (2009) *PLoS ONE* 4(8): e6748). There is also evidence that microRNAs are capable of regulating some class I MHC genes (see Zhu *et al*, (2010) *Am. J.*

5 *Obstet Gynecol* 202(6):592).

[0009] Regulation of class II MHC expression is dependent upon the activity of the MHCII enhanceosome complex. The enhanceosome components (one of the most highly studied components of the enhanceosome complex is the RFX5 gene product (see Villard *et al* (2000) *MCB* 20(10): 3364-3376)) are nearly universally expressed and expression of these components does not seem to control the tissue specific expression of MHC class II genes or their IFN- γ induced up-regulation.

10 Instead, it appears that a protein known as CIITA (class II transactivator) which is a non-DNA binding protein, serves as a master control factor for MCHII expression. In contrast to the other enhanceosome members, CIITA does exhibit tissue specific expression, is up-regulated by IFN- γ , and has been shown to be inhibited by several bacteria and viruses which can cause a down regulation of MHC class II expression (thought to be part of a bacterial attempt to evade immune surveillance (see LeibundGut-Landmann *et al* (2004) *Eur. J. Immunol* 34:1513-1525)).

15 [0010] Regulation of the class I or II genes can be disrupted in the presence of some tumors and such disruption can have consequences on the prognosis of the patients. For example, in some melanomas, an observed reduction in Tap 1, Tap 2 and HLA class I antigens was found to be more common in metastatic melanomas (P<0.05) than in primary tumors (see Kagashita *et al* (1999) *Am Jour of Pathol* 154(3):745-754).

20 [0011] In humans, susceptibility to several diseases is suspected to be tied to HLA haplotype. These diseases include Addison's disease, ankylosing spondylitis, Behçet's disease, Buerger's disease, celiac disease, chronic active hepatitis, Graves' disease, juvenile rheumatoid arthritis, psoriasis, psoriatic arthritis, rheumatoid arthritis, Sjögren syndrome, and lupus erythematosus, among others.

25 [0012] HLA haplotype also plays a major role in transplant rejection. The acute phase of transplant rejection can occur within about 1-3 weeks and usually involves the action of host T lymphocytes on donor tissues due to sensitization of the host system to the donor class I and class II HLA molecules. In most cases, the

triggering antigens are the class I HLAs. For best success, donors are typed for HLA haplotype and matched to the patient recipient as completely as possible. But donation even between family members, which can share a high percentage of HLA haplotype identity, is still often not successful. Thus, in order to preserve the graft

5 tissue within the recipient, the patient often must be subjected to profound immunosuppressive therapy to prevent rejection. Such therapy can lead to complications and significant morbidities due to opportunistic infections that the patient may have difficulty overcoming.

[0013] Cell therapy is a specialized type of transplant wherein cells of a
10 certain type (e.g. T cells reactive to a tumor antigen or B cells) are given to a recipient. Cell therapy can be done with cells that are either autologous (derived from the recipient) or allogenic (derived from a donor) and the cells may be immature cells such as stem cells, or completely mature and functional cells such as T cells. In fact, in some diseases such certain cancers, T cells may be manipulated *ex vivo* to increase
15 their avidity for certain tumor antigens, expanded and then introduced into the patient suffering from that cancer type in an attempt to eradicate the tumor. This is particularly useful when the endogenous T cell response is suppressed by the tumor itself. However, the same caveats apply for cell therapy as apply for more well known solid organ transplants in regards to rejection. Donor T cells express class I
20 HLA antigens and thus are capable of eliciting a rejection response from the recipient's endogenous immune system.

[0014] Thus, there remains a need for compositions and methods for the manipulation of HLA genes and gene expression in cells.

25

SUMMARY

[0014a] Certain exemplary embodiments provide an isolated polypeptide comprising a non-naturally occurring zinc finger protein, wherein the zinc-finger protein comprises four, five or six zinc finger DNA recognition regions designated and ordered F1 to F4, F1 to F5 or F1 to F6 from N-terminus to C-terminus and further
30 wherein the zinc finger protein comprises the zinc finger DNA recognition regions selected from the group consisting of:

- (i) F1: QSSHLTR (SEQ ID NO:1);
- F2: RSDHLTT (SEQ ID NO:2);
- F3: RSDTLSQ (SEQ ID NO:3);

F4: RSADLSR (SEQ ID NO:4);
F5: QSSDLSR (SEQ ID NO:5); and
F6: RSDALTQ (SEQ ID NO:6), wherein the protein binds to the target site set forth in SEQ ID NO:97 in an endogenous HLA class 1 gene;

5 (ii) F1: QKTHLAK (SEQ ID NO:7);
F2: RSDTLSN (SEQ ID NO:8);
F3: RKDVRIT (SEQ ID NO:9);
F4: RSDHLST (SEQ ID NO:10); and
F5: DSSARKK (SEQ ID NO:11), wherein the protein binds to the target site set forth in SEQ ID NO:98 in an endogenous HLA class 1 gene;

10 (iii) F1: QNAHRKT (SEQ ID NO:12);
F2: RSDSLRL (SEQ ID NO:13);
F3: RNDDRKK (SEQ ID NO:14);
F4: RSDHLST (SEQ ID NO:10); and
F5: DSSARKK (SEQ ID NO:11), wherein the protein binds to the target site set forth in SEQ ID NO:99 in an endogenous HLA class 1 gene;

15 (iv) F1: DRSHLSR (SEQ ID NO:15);
F2: RSDDLTR (SEQ ID NO:16);
F3: DRSDLRSR (SEQ ID NO:17); and
F4: QSGHLSR (SEQ ID NO:18), wherein the protein binds to the target site set forth in SEQ ID NO:100 in an endogenous HLA class 1 gene;

20 (v) F1: DRSDLRSR (SEQ ID NO:19);
F2: QSSDLRR (SEQ ID NO:20);
F3: DRSDLRSR (SEQ ID NO:19);
F4: DRSHLAR (SEQ ID NO:21);
F5: RSDDLSK (SEQ ID NO:22); and
F6: DRSHLAR (SEQ ID NO:21), wherein the protein binds to the target site set forth in SEQ ID NO:101 in an endogenous HLA class 1 gene;

25 (vi) F1: SSELLNE (SEQ ID NO:23);
F2: TSSHLSR (SEQ ID NO:24);
F3: QSGDRNK (SEQ ID NO:25);
F4: RSANLAR (SEQ ID NO:26); and
F5: RSDNLRE (SEQ ID NO:27), wherein the protein binds to the target site set forth in SEQ ID NO:102 in an endogenous HLA class 1 gene;

5 (vii) F1: QSGDLTR (SEQ ID NO:28);
F2: RSDDLTR (SEQ ID NO:16);
F3: DQSTLRN (SEQ ID NO:29);
F4: DRSNLSR (SEQ ID NO:30); and
F5: DAFTRTR (SEQ ID NO:31), wherein the protein binds to the
target site set forth in SEQ ID NO:103 in an endogenous HLA class 1 gene;

10 (viii) F1: RSDNLSE (SEQ ID NO:32);
F2: ASKTRKN (SEQ ID NO:33);
F3: TSGNLTR (SEQ ID NO:34); and
F4: RSDALAR (SEQ ID NO:35), wherein the protein binds to the
target site set forth in SEQ ID NO:104 in an endogenous HLA class 1 gene;

15 (ix) F1: DRSALSR (SEQ ID NO:19);
F2: QSGNLAR (SEQ ID NO:36);
F3: DRSALSR (SEQ ID NO:19); and
F4: QSGHLSR (SEQ ID NO:18), wherein the protein binds to the
target site set forth in SEQ ID NO:105 in an endogenous HLA class 1 gene;

20 (x) F1: RSDNLSE (SEQ ID NO:32);
F2: ASKTRKN (SEQ ID NO:33);
F3: QSGHLSR (SEQ ID NO:18);
F4: TSGHLSR (SEQ ID NO:37); and
F5: QSGHLSR (SEQ ID NO:18), wherein the protein binds to the
target site set forth in SEQ ID NO:106 in an endogenous HLA class 1 gene;

25 (xi) F1: RSADLTR (SEQ ID NO:38);
F2: QSGDLTR (SEQ ID NO:28);
F3: QSGNLAR (SEQ ID NO:36); and
F4: QSGDLTR (SEQ ID NO:28), wherein the protein binds to the
target site set forth in SEQ ID NO:107 in an endogenous HLA class 1 gene;

30 (xii) F1: QSGHLSR (SEQ ID NO:18);
F2: RSDHLST (SEQ ID NO:10);
F3: QSADRTK (SEQ ID NO:39);
F4: TSGSLSR (SEQ ID NO:40); and
F5: QSADRTK (SEQ ID NO:39), wherein the protein binds to the
target site set forth in SEQ ID NO:108 in an endogenous HLA class 1 gene;

(xiii) F1: QSGDLTR (SEQ ID NO:28);

F2: RSDHLST (SEQ ID NO:10);
F3: QSADRTK (SEQ ID NO:39);
F4: RSDNLSA (SEQ ID NO:41); and
F5: RSDNRTT (SEQ ID NO:42), wherein the protein binds to the
5 target site set forth in SEQ ID NO:109 in an endogenous HLA class 1 gene;
(xiv) F1: QRSNLVR (SEQ ID NO:43);
F2: DRSALAR (SEQ ID NO:44);
F3: QSSDLRR (SEQ ID NO:20);
F4: RSDDLTR (SEQ ID NO:16); and
F5: RSDDLTR (SEQ ID NO:16), wherein the protein binds to the
10 target site set forth in SEQ ID NO:110 in an endogenous HLA class 1 gene; and
(xv) F1: RSDDLTR (SEQ ID NO:16);
F2: DRSDLSR (SEQ ID NO:17);
F3: QSGHLSR (SEQ ID NO:18);
F4: RSDHLSA (SEQ ID NO:45); and
F5: ESRYLMV (SEQ ID NO:46), wherein the protein binds to the target site
set forth in SEQ ID NO:111 in an endogenous HLA class 1 gene.

[0015] Disclosed herein are methods and compositions for manipulating HLA
gene complexes or HLA gene expression. In particular, provided herein are methods
20 and compositions for modulating expression of an HLA gene so as to treat HLA-
related disorders, for example human disorders related to HLA haplotype of the
individual. Additionally, provided herein are methods and compositions for deleting
or repressing an HLA gene to produce an HLA null cell, cell fragment (*e.g.* platelet),
tissue or whole organism. Additionally, these methods and compositions may be used
25 to create a cell, cell fragment, tissue or organism that is null for just one HLA gene, or
more than one HLA gene, or is completely null for all HLA genes. In certain

embodiments, the HLA null cells or tissues are human cells or tissues that are advantageous for use in transplants.

[0016] Thus, in one aspect, engineered DNA-binding domains (*e.g.*, zinc finger proteins or TALE DNA binding domain proteins) that modulate expression of an HLA allele are provided. In certain embodiments, the DNA binding domain comprises engineered zinc finger proteins that are non-naturally occurring as well as zinc finger proteins whose recognition helices have been altered (*e.g.*, by selection and/or rational design) to bind to a pre-selected target site. Any of the zinc finger proteins described herein may include 1, 2, 3, 4, 5, 6 or more zinc fingers, each zinc finger having a recognition helix that binds to a target subsite in the selected sequence(s) (*e.g.*, gene(s)). In some embodiments, one or more of the recognition helices of the zinc finger domains of the zinc finger protein is non-naturally occurring. In certain embodiments, the zinc finger proteins have the recognition helices shown in Table 1. In other embodiments, the zinc finger proteins bind to the target sites shown in Table 2. In other embodiments, the DNA binding domain comprises a TALE DNA binding domain (*e.g.*, a TALE DNA binding domain comprising naturally occurring and/or non-naturally occurring TALE binding domains).

[0017] In certain embodiments, the DNA-binding proteins (*e.g.*, zinc finger proteins (ZFPs) or TALE DNA binding proteins) as described herein can be placed in operative linkage with a regulatory domain (or functional domain) as part of a fusion protein. In certain embodiments, the regulatory domain is an activation domain or repression domain for fusion with the DNA-binding domain, and such fusion proteins (*i.e.* ZFP- or TALE-transcription factor fusions: ZFP-TF and TALE-TF respectively) can be used either to activate or to repress gene expression. In some embodiments, repressors are provided which are capable of preferentially binding to HLA genes or modulators of HLA gene expression. In certain embodiments, the activity of the regulatory domain is regulated by an exogenous small molecule or ligand such that interaction with the cell's transcription machinery will not take place in the absence of the exogenous ligand. Such external ligands control the degree of interaction of the ZFP-TF or TALE- TF with the transcription machinery.

[0018] In one embodiment, the repressors are capable of binding to a specific HLA A, HLA B or HLA C transcriptional regulatory region and are able to repress expression in only one of the above genes. In another aspect, a repressor is provided that is capable of interacting with transcriptional regulatory regions common to HLA

A, HLA B and HLA C such that all three genes are regulated with one DNA binding domain (*e.g.*, ZFP TF or TALE TF). In another embodiment, a repressor is capable of binding to a regulator of HLA class II expression or function (*e.g.* CIITA or RFX5) to repress its activity and thus repress HLA class II expression or function.

5 [0019] In other embodiments, repressing DNA binding domain-transcription factor fusions are provided which preferentially bind to known HLA haplotypes to repress expression of only one allele.

[0020] In another aspect, DNA-binding domain-transcription factor fusions that specifically activate the expression of HLA genes are provided. Such fusions 10 may up-regulate a class of HLA genes by increasing expression of a regulator, or may cause expression of such a class in tissues where these genes are not normally expressed. In another embodiment, provided are DNA-binding domain- transcription factor fusions (*e.g.*, ZFP TFs or TALE TFs) that activate specific HLA genes as desired.

15 [0021] In another aspect, the fusion protein comprises a DNA-binding protein (*e.g.*, ZFP or TALE) as described herein in operative linkage with a functional domain comprising a nuclease (*e.g.*, ZFNs or TALENs). In certain embodiments, provided herein are zinc finger nucleases (ZFNs) or TALE DNA binding domains fused to a nuclease (TALENs) that cleave an HLA gene. In certain embodiments, the ZFNs 20 and/or TALENs bind to target sites in a human HLA class I gene and/or target sites in a human HLA class II gene. In some embodiments, cleavage within the HLA gene(s) with these nucleases results in permanent disruption (*e.g.*, mutation) of the HLA gene. In certain embodiments, two pairs of ZFNs and/or TALENs may be used to cause larger deletions. The deletions may comprise a small portion of one HLA gene, or 25 HLA regulator gene, or may comprise larger segments. In some embodiments, the deletions caused by the ZFNs or TALENs may delete one or more HLA genes or may delete an entire HLA gene complex (*i.e.*, all of the class I HLA genes, or all of the HLA class II genes). The deletions may also encompass the deletion of a subset of a class of HLA genes. The zinc finger DNA binding proteins may include 1, 2, 3, 4, 5, 30 6 or more zinc fingers, each zinc finger having a recognition helix that binds to a target subsite in the target gene. In certain embodiments, the zinc finger proteins comprise 4 or 5 or 6 fingers (where the fingers are designated F1, F2, F3, F4, F5 and F6 and ordered F1 to F4 or F5 or F6 from N-terminus to C-terminus) and the fingers comprise the amino acid sequence of the recognition regions shown in Table 1.

[0022] Any of the ZFN or TALEN proteins described herein may further comprise a cleavage domain and/or a cleavage half-domain (e.g., a wild-type or engineered *FokI* cleavage half-domain). Thus, in any of the ZFNs or TALENs described herein, the nuclease domain may comprise a wild-type nuclease domain or 5 nuclease half-domain (e.g., a *FokI* cleavage half domain). In other embodiments, the ZFNs or TALENs comprise engineered (non-naturally occurring) nuclease domains or half-domains, for example engineered *FokI* cleavage half domains that form obligate heterodimers. *See, e.g.*, U.S. Patent Publication No. 20080131962.

[0023] In another aspect, the disclosure provides a polynucleotide encoding 10 any of the proteins described herein. Any of the polynucleotides described herein may also comprise sequences (donor or patch sequences) for targeted insertion into the HLA genes.

[0024] In yet another aspect, a gene delivery vector comprising any of the polynucleotides described herein is provided. In certain embodiments, the vector is 15 an adenovirus vector (e.g., an Ad5/F35 vector), a lentiviral vector (LV) including integration competent or integration-defective lentiviral vectors, or an adenovirus associated viral vector (AAV). Thus, also provided herein are adenovirus (Ad) vectors, LV or adenovirus associate viral vectors (AAV) comprising a sequence encoding at least one nuclease as described herein (e.g., ZFN or TALEN) and/or a 20 donor sequence for targeted integration into a target gene. In certain embodiments, the Ad vector is a chimeric Ad vector, for example an Ad5/F35 vector. In certain embodiments, the lentiviral vector is an integrase-defective lentiviral vector (IDLV) or an integration competent lentiviral vector. In certain embodiments the vector is pseudo-typed with a VSV-G envelope, or with other envelopes.

[0025] In additional embodiments, the target gene is a gene (e.g., in a human 25 cell) that regulates HLA expression (an HLA regulator gene). In certain embodiments, a CTIIA, a RFX5 gene, aTAP1, TAP2 or tapasin gene, or combination thereof are targeted for regulation (e.g., activation, repression and/or inactivation). In some embodiments, the target gene encodes a microRNA capable of regulating HLA 30 genes. The vectors described herein may also comprise donor sequences. In additional embodiments, the donor sequences comprise human HLA genes or HLA regulator genes that are not endogenous to the host cell. In some embodiments, the HLA genes or HLA regulator genes of interest are inserted into the location of the endogenous HLA genes or HLA regulator genes, and in other embodiments the HLA

genes or HLA regulator genes of interest are inserted into randomly selected loci, or into a separate locus after genome-wide delivery. In some embodiments, the separate locus for HLA transgene or HLA regulator transgene insertion is the PPP1R12C locus (see U.S Patent Publication Number 20080299580). In other embodiments, the HLA 5 transgene or HLA regulator transgene is inserted into a CCR-5 locus. In some aspects, the donor comprises another nucleic acid of interest. By way of example only, this donor may contain a gene encoding a polypeptide of interest, or it may comprise a sequence encoding a structural RNA (shRNA, miRNA, RNAi etc.). In some embodiments, cells are provided wherein an HLA gene or HLA regulator gene 10 of interest has been manipulated in a desired fashion (e.g. knocked-out, corrected etc.) and a donor and one or more additional of ZFNs and/or TALENs are provided to insert the donor into another locus (e.g. AAVS1).

15 [0026] In certain embodiments, a single vector comprises sequences encoding one or more nucleases as described herein (e.g., ZFNs and/or TALENs) and the donor sequence(s). In other embodiments, the donor sequence(s) are contained in a first vector and the nuclease-encoding sequences are present in a second vector.

20 [0027] In yet another aspect, the disclosure provides a cell (e.g., an isolated cell) comprising any of the proteins, polynucleotides and/or vectors described herein. In certain embodiments, the cell is selected from the group consisting of a stem/progenitor cell, a lymphocyte, a B cell, or a T-cell (e.g., CD4+ T-cell). In other embodiments, the cell is a cell fragment, including, but not limited to a platelet.

25 [0028] In another aspect, described herein are methods of inactivating an HLA gene or HLA regulator gene in a cell by introducing one or more proteins, polynucleotides and/or vectors into the cell as described herein. In any of these methods the nucleases may induce targeted mutagenesis, targeted deletions, targeted insertions of cellular DNA sequences, and/or facilitate targeted recombination at a predetermined chromosomal locus. Thus, in certain embodiments, the nucleases (e.g., ZFNs and/or TALENs) delete and/or insert one or more nucleotides at the target gene. In some embodiments the HLA gene is inactivated by nuclease (ZFN and/or TALEN) 30 cleavage followed by non-homologous end joining. In other embodiments, a genomic sequence in the target gene is replaced, for example using one or more pairs of ZFNs (or vector encoding said ZFNs) and/or one or more TALENs as described herein and a “donor” sequence that is inserted into the gene following targeted cleavage with the ZFN(s) and/or TALEN(s). The donor sequence may be present in the nuclease fusion

vector, present in a separate vector (*e.g.*, Ad, AAV or LV vector) or, alternatively, may be introduced into the cell using a different nucleic acid delivery mechanism. In some embodiments, the ZFNs and/or TALENs are delivered using the mRNAs that encode them. In some embodiments, the nucleic acids may be delivered by

5 electroporation or another technique suitable for the delivery of naked nucleic acid.

[0029] In another aspect, methods of using the DNA-binding proteins and fusions thereof for mutating an HLA gene and/or inactivating HLA function in a cell or cell line are provided. Thus, a method for inactivating an HLA gene in a human cell is provided, the method comprising administering to the cell any of the proteins 10 or polynucleotides described herein. Methods are also provided herein for altering MHC function in any model organism.

[0030] In another aspect, the compositions and methods described herein can be used, for example, in the treatment or prevention or amelioration of any HLA-related disorder (*i.e.*, related to HLA haplotype). The methods typically comprise (a)

15 cleaving an endogenous HLA gene or HLA regulator gene in an isolated cell (*e.g.*, T-cell or lymphocyte) using a nuclease (*e.g.*, ZFN or TALEN) such that the HLA or HLA regulator gene is inactivated; and (b) introducing the cell into the subject,

thereby treating or preventing an HLA-related disorder. In certain embodiments, the HLA-related disorder is graft-versus-host disease (GVHD). The nuclease(s) can be

20 introduced as mRNA, in protein form and/or as a DNA sequence encoding the nuclease(s). In certain embodiments, the isolated cell introduced into the subject

further comprises additional genomic modification, for example, an integrated exogenous sequence (into the cleaved HLA or HLA regulatory gene or a different gene, for example a safe harbor gene) and/or inactivation (*e.g.*, nuclease-mediated) of

25 additional genes, for example one or more TCR genes. The exogenous sequence may be introduced via a vector (*e.g.* Ad, AAV, LV), or by using a technique such as electroporation. In some aspects, the composition may comprise isolated cell fragments and/or differentiated cells.

[0031] In some embodiments, nuclease fusions as described herein may be

30 utilized for targeting stem cells such as induced pluripotent stem cells (iPSC), human embryonic stem cells (hES), mesenchymal stem cells (MSC), hematopoietic stem cells (HSC) or neuronal stem cells wherein the activity of the nuclease fusion will result in an HLA allele containing a deletion. In some embodiments, the methods

may be used to create stem cells in which more than one HLA gene has been altered.

In other embodiments, the invention provides methods for producing stem cells that have an HLA null phenotype. In some aspects, the stem cells may be null for one or more or all HLA class II gene expression. In other aspects, the stem cells may be null for one or more or all HLA class I gene expression. In some aspects, the stem cells 5 are null for all HLA gene expression. In other embodiments, the stem cells that have been modified at the HLA locus/loci are then differentiated.

[0032] Also provided are pharmaceutical compositions comprising the modified stem cells. Such pharmaceutical compositions may be used prophylactically or therapeutically and may comprise iPSCs, hES, MSCs, HSCs or combinations 10 and/or derivatives thereof. In other embodiments, cells, cell fragments (*e.g.*, platelets) or tissues derived from such modified stem cells are provided such that such tissues are modified in the HLA loci as desired. In some aspects, such cells are partially differentiated (*e.g.* hematopoietic stem cells) while in others fully differentiated cells are provided (*e.g.* lymphocytes or megakarocytes) while in still others, fragments of 15 differentiated cells are provided. In other embodiments, stem cells, and/or their differentiated progeny are provided that contain an altered HLA or HLA regulator gene or genes, and they also can contain an additional genetic modification including a deletion, alteration or insertion of a donor DNA at another locus of interest.

[0033] In some embodiments, cells treated with the DNA-binding domains or 20 fusion proteins as described herein (*e.g.*, ZFP-TF, TALE DNA binding domains TFs, ZFNs, and/or TALENs) may be mature cells such as CD4+ T cells or NK cells. Such cells may comprise a protein comprising a DNA-binding domain as described herein for regulation of an HLA gene or HLA regulator gene, or may comprise a nuclease fusion (*e.g.*, ZFN or TALEN) for introduction of a deletion and/or insertion into an 25 HLA gene. In some aspects, such ZFN or TALEN comprising cells may additionally comprise an exogenous DNA sequence. In some aspects, the mature cells may be used for cell therapy, for example, for a T cell transplant. In other embodiments, the cells for use in T cell transplant contain another gene modification of interest. In one aspect, the T cells contain an inserted chimeric antigen receptor (CAR) specific for a 30 cancer marker. In a further aspect, the inserted CAR is specific for the CD19 marker characteristic of B cell malignancies. Such cells would be useful in a therapeutic composition for treating patients without having to match HLA haplotype, and so would be able to be used as an “off-the-shelf” therapeutic for any patient in need thereof. In some aspects, cells in which genes encoding the TCR α and/or TCR β

chains have been manipulated or in which genes encoding TCR chains with desired specificity and affinity have been introduced are provided. In other embodiments, HLA modified platelets are provided for therapeutic use in treatment of disorders such as thromobytopenia or other bleeding disorders.

5 [0034] In still further aspects, the invention provides methods and compositions for the generation of specific model systems for the study of HLA disorders. In certain embodiments, models in which mutant HLA alleles are generated in embryonic stem cells for the generation of cell and animal lines are provided. In certain embodiments, the model systems comprise *in vitro* cell lines, 10 while in other embodiments, the model systems comprise transgenic animals. In other embodiments, the invention provides methods and compositions for correcting a mutated HLA gene or HLA regulator and also provides methods and compositions for replacing one HLA allele with another.

15 [0035] In some embodiments, model systems are provided for HLA disorders wherein the target alleles (e.g., specific HLA haplotypes) are tagged with expression markers. In certain embodiments, mutant alleles (e.g., mutant HLA or HLA regulators) are tagged. In certain embodiments, the model systems comprise *in vitro* cell lines, while in other embodiments, the model systems comprise transgenic animals.

20 [0036] Additionally, pharmaceutical compositions containing the nucleic acids and/or DNA-binding domains (or fusion proteins comprising the DNA-binding domains) are also provided. For example, certain compositions include a nucleic acid comprising a sequence that encodes one of the ZFPs and/or TALE DNA binding domains described herein operably linked to a regulatory sequence, combined with a 25 pharmaceutically acceptable carrier or diluent, wherein the regulatory sequence allows for expression or repression of the nucleic acid in a cell. In certain embodiments, the ZFPs and/or TALE DNA binding domains encoded are specific for an HLA allele. Protein based compositions include one or more ZFPs TALE DNA binding domains as disclosed herein and a pharmaceutically acceptable carrier or diluent.

30 [0037] Any of the methods described herein can be practiced *in vitro*, *in vivo* and/or *ex vivo*. In certain embodiments, the methods are practiced *ex vivo*, for example to modify T-cells or NK cells prior to use for treating a subject in need thereof.

[0038] These and other aspects will be readily apparent to the skilled artisan in light of disclosure as a whole.

BRIEF DESCRIPTION OF THE DRAWINGS

5 [0039] **Figure 1** depicts a schematic of some of the genes of the MHC Class I and Class II clusters.

[0040] **Figure 2, panels A and B,** depicts gels displaying the results of Cel-I mismatch assays (Surveyor™, Transgenomics) for ZFNs targeting HLA A3 (Figure 2A) and HLA A2 (Figure 2B). The assay analyzes the percent mismatch with an 10 amplified genomic DNA fragment, and thus allows quantitation of the amount of alterations (%) in the DNA sequence that occurred after NHEJ repair of the ZFN generated DSB. Both gels display the results for a mock transfection, transfection with a GFP encoding plasmid, and transfection with plasmids encoding the ZFN pairs indicated beneath the lanes of each gel into HEK293 cells. The percent gene 15 modification is indicated at the bottom of the lanes.

[0041] **Figure 3, panels A to D,** depict the results of a FACS analysis of HEK293 cells in which either HLA A2, HLA A3 or both HLA A2 and A3 have been disrupted following specific ZFN treatment. Figure 3A (“parental”) depicts the 20 parental HEK293 cells lacking any ZFN treatment. The column on the left indicates staining for the HLA A2 allele while the column on the right indicates staining for the HLA A3 allele. The furthermost left peak in each panel indicates the isotype control (background). In the parental cells, the peak to the furthest right indicates the results for the antibodies staining a B-LCL clone (positive control). The second to most left peak indicates the amount of A2 or A3 positive cells prior to cytokine (IFN gamma) 25 treatment, while the second furthest to the right peak indicates the results for HLA A2 or A3 expression following cytokine treatment. Figures 3B to 3D, corresponding to cell clones 18-1 (A2+A3-) (Figure 3B), 8.18 (A2-A3+) (Figure 3C) and 83 (A2-A3-) (Figure 3D) contain the same analyses as shown in Figure 3A (except the positive B cell staining the line farthest to the right in the parental panels is not shown). Thus, 30 these data indicate that when the allele of interest is disrupted, no expression of the cell marker is observed, even upon cytokine stimulation.

[0042] **Figure 4, panels A and B,** are graphs depicting the analysis of cell lysis of the HLA-A knock-out HEK293 clones, 18-1, 8.18 and B cell clones (described above for Figure 3) by specific CTLs targeting HLA A2 or HLA A3,

respectively. In this experiment, CTLs restricted to either HLA A2 or HLA A3 were used in combination with the specific peptide epitope (SEQ ID NO:135 and SEQ ID NO:136) that, when displayed on the HLA complex, stimulates CTL action. Figure 4A depicts the results when using HLA A3 specific CTLs and HEK293 target cells with increasing concentrations of their peptide antigen. Cells that contain the unmodified A3 HLA gene product are lysed (parental, 8.18 and B-LCL). In Figure 4B, a lysis experiment was carried out using CTLs specific for HLA A2 in conjunction with a specific peptide antigen. When increasing concentrations of peptide are used, the CTLs are able to lyse those cells containing an intact HLA A2 gene product (parental HEK293, 18-1 and B-LCL). Thus, when expression of the HLA A gene targeted by the CTLs is disrupted, the cells are no longer susceptible to CTL directed lysis.

[0043] **Figure 5, panels A and B,** depict the results of a FACS analysis of HLA A2 staining. In this experiment, primary T-cells were nucleofected with varying amounts of mRNAs (2.5 μ g shown in left panels, 5.0 μ g shown in middle panels and 10 μ g shown in right panels) encoding the HLA A2 specific ZFNs. Figure 5A depicts the results using standard cell culture conditions following transfection, while Figure 5B depicts the results using the “transient cold shock” methodology. Up to nearly 42% of the cells can display an HLA A2 disruption characteristic using the “cold shock” methodology.

[0044] **Figure 6** depicts a gel displaying the results of a Cel-I mismatch analysis for the primary T cells analyzed in Figure 5. The lanes depict the results using ZFN pairs with wild type *Fok* I catalytic domain (“wt”) and ZFN pairs with an “ELD/KKR” heterodimeric domains (“mut”) at the indicated ZFN concentrations (2.5 μ g shown in left panels, 5.0 μ g shown in middle panels and 10 μ g shown in right panels). The percent gene modification detected by this assay (“Targeted disruption (%)) is shown in the bottom of each lane and the results are consistent with the FACS analysis.

[0045] **Figure 7, panels A and B,** depict gels displaying the results of a Cel-I mismatch analysis for ZFNs specific for the HLA C (Figure 7A) and HLA B (Figure 7B) genes. The arrows indicate the band on the gel indicative of gene modification.

[0046] **Figure 8, panels A and B,** depict gels displaying the results of a Cel-I mismatch analysis for ZNFs specific for a target sequence downstream of the HLA C gene (“HLA C-down”) and a target sequence upstream of the HLA B gene (“HLA B-

up”). Figure 8A depicts the results for the HLA C-down specific ZFN pair where ZFNs containing a wild type *FokI* catalytic domain (wt) and the ZFN pair containing an EL/KK heterodimeric *FokI* domain (mut) are shown. The arrow depicts the band indicating the mismatch. The percent gene modification detected is shown at the 5 bottom of each lane (“% NHEJ”). Figure 8B depicts the results for two HLA B-up ZFN pairs where the arrow point out the bands indicative of gene modification.

10 [0047] **Figure 9, panels A and B,** illustrates an experiment designed to create a large deletion that includes both the HLA B and the HLA C locus. Figure 9A is a schematic of the HLA gene complex in the area of HLA B and HLA C, and the regions targeted by the HLA B-up and HLA C-down ZFNs are indicated. The location of the primers used for the PCR to visualize the deletion are also indicated. Figure 9B depicts the results of the deletion specific PCR following cleavage with the HLA B-up and HLA C-down ZFNs in K562 cells. The lanes on the left side of the gel are a dilution series of a deletion PCR product that we inserted into a plasmid in 15 order to quantitate the signal from the PCR. The deletion PCR was performed on DNAs isolated 3 and 10 days following nucleofection, and the ZFNs used contained either the wild-type (“wt”) or mutated (“mut”) *FokI* catalytic domain (as discussed above in Figure 8). The results indicate that at day 3, approximately 5% of the alleles contained the HLA B and HLA C deletion.

20 [0048] **Figure 10, panels A and B,** depict gels displaying the results of cleavage using ZFNs targeting HLA regulatory genes in HEK293 cells. Figure 10A depicts the results of a Cel I mismatch assay with ZFNs targeted the TAP1 gene, while Figure 10B depicts the results when the ZFNs targeted the TAP2 gene. ZFNs used are indicated above the appropriate lanes. These results indicate that these ZFNs 25 are active in cleaving target DNA.

[0049] **Figure 11** depicts a gel displaying the results of a Cel-I mismatch assay using ZFNs (ZFN numbers are indicated above lanes 1 and 2) targeting the Tapasin gene in HEK293 cells. The percent gene modification is indicated at the bottom of each lane. These data reveal that this ZFN pair is active against this target.

30 [0050] **Figure 12** depicts a gel displaying the results of a Cel-I mismatch assay using ZFNs targeting either a target location upstream of the DPB2 gene (DPB2up) or downstream of the DRA gene (DRAdown) in K562 cells. The transfections used the indicated ZFNs that contained either wild type *FokI* catalytic domains (“wt”) or the EL/KK heterodimeric *FokI* catalytic domain (“mut”). The

percent gene modification as measured by this assay is indicated at the bottom of each lane. The “wt” lanes show duplicate transfections performed on two different transfection dates.

5 [0051] **Figure 13** depicts a gel displaying the results of a deletion PCR similar to that performed in Figure 9. As described for Figure 9, the lanes on the left side of the gel contain a dilution series of subcloned PCR product for use in quantitation of the frequency of alleles containing the deletion. The deletion PCR was performed on DNA isolated from cells at day 3 or day 10 after the transfection, and the ZFNs used contained either wild type *Fok* I catalytic domains (“wt”) or the EL/KK heterodimer 10 10 *Fok*I catalytic domains (“mut”). The results indicate that approximately 0.04% of the alleles contained the large deletion.

15 [0052] **Figure 14** depicts sequencing results obtained by sequencing the deletion PCR product shown in Figure 13. Lines 1-4 (SEQ ID NO:137) are individual nucleic acids from the PCR, while line 5 (SEQ ID NO:138) displays the genomic sequence surrounding the 15909 ZFN target site and sequence downstream thereof. Line 6 (SEQ ID NO:139) depicts the genomic sequence surrounding the 15873 target site and sequence upstream thereof. Line 7 (SEQ ID NO:137) shows the consensus sequence from lines 1-4. These results indicate that following cleavage with the DBP2 up and DRA down ZFNs, a large deletion has been generated by rejoining of 20 the ends such that the resultant DNAs contain the distal target site of each ZFN pair.

25 [0053] **Figure 15** depicts a gel displaying the results following a Cel-I mismatch assay as described above. ZFNs targeting either the HLA class II regulator genes CIITA or RFX5 were used in K562 cells, and the percent gene modification is indicated at the bottom of the lanes. Control lanes contain the results of experiments done either with no added ZFNs (“mock”) or transfected with a GFP encoding plasmid (“gfp”) are also shown.

30 [0054] **Figure 16** depicts a gel displaying the results following a Cel-I mismatch assay as described above. The CIITA targeting ZFNs were used in either K562 cells (“K”) or RAJI cells (“R”). The percent gene modification as detected by this assay is shown at the bottom of the lanes, and the arrows show the bands indicative of modification activity. These results demonstrate that the CIITA targeting ZFNs can work in RAJI cells as well as K562 cells. “n.c.” indicates the negative control done without any ZFN encoding DNA during the transfection.

[0055] **Figure 17, panels A to D,** depict the results of a FACS analysis done on T cells that had been previously been made transgenic for a chimeric antigen receptor that targets CD19 (CD19CAR). These CD19CAR modified T cells were nucleofected with mRNAs encoding ZFNs that target the HLA A2 gene and HLA-A2 negative cells were enriched by negative bead sorting with an HLA-A2 antibody and a FACS assay was performed using a HLA A2 specific antibody. The results indicate that the HLA A2 knock out cells were be enriched such that the population contained 95.3% HLA A2 knock outs.

[0056] **Figure 18** is a graph depicting the results of a lysis assay with HLA A2-specific CD19CAR containing T cells which had either been treated with the HLA A2-specific ZFNs (A2neg CD19RCAR-T cells) and enriched using the HLA-A2 specific antibody, or had been mock transfected (A2posCD19RCAR-T cells). Cells were incubated with increasing amounts of the specific peptide epitope. As a positive control, A2pos B cells were used. The results indicate that the cells lacking the HLA A2 gene product are resistant to HLA A2-specific CTL induced lysis.

[0057] **Figure 19, panels A to G,** depict the results from several FACS analyses. mRNAs encoding ZFNs specific for either TCR β (“TRBC,” Figure 19A to Figure 19D) or TCR α (“TRAC,” Figure 19E to Figure 19G) were used in a range from 2.5 μ g to 10 μ g as indicated above the FACS. The assay is designed to score CD3 on the cell surface, a complex that is dependent on the presence of the TCR. The results demonstrate that the TCR β specific ZFNs can cause approximately 9% of the cells in the population to lose the CD3 marker while the TCR α specific ZFNs can cause approximately 28% of cells to lose the CD3 marker.

[0058] **Figure 20, panels A and B,** depict a gel displaying the results of a Cel-I assay as described above to assess the amount of gene modification present when either mRNAs encoding the TCR β -specific ZFNs (TRBC, Figure 20A) or encoding the TCR α -specific ZFNs (TRAC, Figure 20B) are used. In this example, mRNAs were nucleofected and cultured according to either standard conditions or using the “transient cold shock” conditions. The results agree generally with the results from Figure 19 and indicate that both ZFN sets are capable of cleaving their intended targets.

DETAILED DESCRIPTION

[0059] Disclosed herein are DNA binding domains (*e.g.*, ZFP and/or TALE DNA binding proteins) and fusion proteins comprising these DNA binding domains (*e.g.*, ZFNs, TALENs, ZFP-TFs and TALE-TFs) for targeting an HLA gene or an HLA regulator. The proteins described herein can repress or activate a specific HLA gene, and change its expression. Similarly, DNA-binding proteins as described herein can target a HLA regulator and through modulating its expression, can cause a change in HLA expression. Also disclosed and provided herein are compositions including ZFNs and/or TALENs and methods for altering an HLA gene. These include compositions and methods using engineered DNA-binding domains, *i.e.*, non-naturally occurring proteins which bind to a predetermined nucleic acid target sequence. The DNA binding domains and fusion proteins comprising these DNA-binding domains as described herein can act efficiently and specifically on a desired HLA gene or genes, and can result in a deletion of the specific gene and/or the introduction of an alternate gene of interest into the targeted locus. Cells targeted in this manner can be used as therapeutics, for example, transplants, or can be used to generate either *in vitro* or *in vivo* model systems to study HLA gene function. Such cells can also be used as drug screening tools to isolate and characterize small molecules or other types of therapeutics for compounds that will act upon HLA expression. Cells can also be generated in which following knock out of the desired HLA genes, other HLA genes may be inserted to change the HLA gene products that are expressed on the cell's surface. Additionally, other genes of interest may be inserted into cells in which the HLA genes have been manipulated.

[0060] Thus, the methods and compositions described herein provide methods for treatment of HLA related disorders, and these methods and compositions can comprise zinc finger transcription factors capable of modulating target genes as well as engineered zinc finger nucleases.

General

[0061] Practice of the methods, as well as preparation and use of the compositions disclosed herein employ, unless otherwise indicated, conventional techniques in molecular biology, biochemistry, chromatin structure and analysis, computational chemistry, cell culture, recombinant DNA and related fields as are within the skill of the art. These techniques are fully explained in the literature. *See,*

for example, Sambrook *et al.* MOLECULAR CLONING: A LABORATORY MANUAL, Second edition, Cold Spring Harbor Laboratory Press, 1989 and Third edition, 2001; Ausubel *et al.*, CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, John Wiley & Sons, New York, 1987 and periodic updates; the series METHODS IN ENZYMOLOGY, 5 Academic Press, San Diego; Wolffe, CHROMATIN STRUCTURE AND FUNCTION, Third edition, Academic Press, San Diego, 1998; METHODS IN ENZYMOLOGY, Vol. 304, "Chromatin" (P.M. Wasserman and A. P. Wolffe, eds.), Academic Press, San Diego, 1999; and METHODS IN MOLECULAR BIOLOGY, Vol. 119, "Chromatin Protocols" (P.B. Becker, ed.) Humana Press, Totowa, 1999.

10

Definitions

[0062] The terms "nucleic acid," "polynucleotide," and "oligonucleotide" are used interchangeably and refer to a deoxyribonucleotide or ribonucleotide polymer, in linear or circular conformation, and in either single- or double-stranded form. For the purposes of 15 the present disclosure, these terms are not to be construed as limiting with respect to the length of a polymer. The terms can encompass known analogues of natural nucleotides, as well as nucleotides that are modified in the base, sugar and/or phosphate moieties (e.g., phosphorothioate backbones). In general, an analogue of a particular nucleotide has the same base-pairing specificity; *i.e.*, an analogue of A will base-pair with T.

20 [0063] The terms "polypeptide," "peptide" and "protein" are used interchangeably to refer to a polymer of amino acid residues. The term also applies to amino acid polymers in which one or more amino acids are chemical analogues or modified derivatives of corresponding naturally-occurring amino acids.

25 [0064] "Binding" refers to a sequence-specific, non-covalent interaction between macromolecules (e.g., between a protein and a nucleic acid). Not all components of a binding interaction need be sequence-specific (e.g., contacts with phosphate residues in a DNA backbone), as long as the interaction as a whole is sequence-specific. Such interactions are generally characterized by a dissociation constant (K_d) of 10^{-6} M^{-1} or lower. "Affinity" refers to the strength of binding: 30 increased binding affinity being correlated with a lower K_d .

[0065] A "binding protein" is a protein that is able to bind non-covalently to another molecule. A binding protein can bind to, for example, a DNA molecule (a DNA-binding protein), an RNA molecule (an RNA-binding protein) and/or a protein molecule (a protein-binding protein). In the case of a protein-binding protein, it can bind to itself (to

form homodimers, homotrimers, *etc.*) and/or it can bind to one or more molecules of a different protein or proteins. A binding protein can have more than one type of binding activity. For example, zinc finger proteins have DNA-binding, RNA-binding and protein-binding activity.

5 [0066] A "zinc finger DNA binding protein" (or binding domain) is a protein, or a domain within a larger protein, that binds DNA in a sequence-specific manner through one or more zinc fingers, which are regions of amino acid sequence within the binding domain whose structure is stabilized through coordination of a zinc ion. The term zinc finger DNA binding protein is often abbreviated as zinc finger protein or ZFP.

10 [0067] A "TALE DNA binding domain" or "TALE" is a polypeptide comprising one or more TALE repeat domains/units. The repeat domains are involved in binding of the TALE to its cognate target DNA sequence. A single "repeat unit" (also referred to as a "repeat") is typically 33-35 amino acids in length and exhibits at least some sequence homology with other TALE repeat sequences within a naturally occurring TALE protein.

15 [0068] Zinc finger binding domains can be "engineered" to bind to a predetermined nucleotide sequence, for example via engineering (altering one or more amino acids) of the recognition helix region of a naturally occurring zinc finger protein. Similarly, TALEs can be "engineered" to bind to a predetermined nucleotide sequence, for example by engineering of the amino acids involved in DNA binding

20 (the repeat variable diresidue or RVD region). Therefore, engineered zinc finger proteins or TALE proteins are proteins that are non-naturally occurring. Non-limiting examples of methods for engineering zinc finger proteins and TALEs are design and selection. A designed protein is a protein not occurring in nature whose design/composition results principally from rational criteria. Rational criteria for

25 design include application of substitution rules and computerized algorithms for processing information in a database storing information of existing ZFP or TALE designs and binding data. See, for example, US Patents 6,140,081; 6,453,242; and 6,534,261; see also WO 98/53058; WO 98/53059; WO 98/53060; WO 02/016536 and WO 03/016496.

30 [0069] A "selected" zinc finger protein or TALE is a protein not found in nature whose production results primarily from an empirical process such as phage display, interaction trap or hybrid selection. See *e.g.*, US 5,789,538; US 5,925,523; US 6,007,988; US 6,013,453; US 6,200,759; WO 95/19431; WO 96/06166;

WO 98/53057; WO 98/54311; WO 00/27878; WO 01/60970 WO 01/88197 and WO 02/099084.

[0070] "Recombination" refers to a process of exchange of genetic information between two polynucleotides. For the purposes of this disclosure,

5 "homologous recombination (HR)" refers to the specialized form of such exchange that takes place, for example, during repair of double-strand breaks in cells via homology-directed repair mechanisms. This process requires nucleotide sequence homology, uses a "donor" molecule to template repair of a "target" molecule (*i.e.*, the one that experienced the double-strand break), and is variously known as "non-
10 crossover gene conversion" or "short tract gene conversion," because it leads to the transfer of genetic information from the donor to the target. Without wishing to be bound by any particular theory, such transfer can involve mismatch correction of heteroduplex DNA that forms between the broken target and the donor, and/or "synthesis-dependent strand annealing," in which the donor is used to resynthesize
15 genetic information that will become part of the target, and/or related processes. Such specialized HR often results in an alteration of the sequence of the target molecule such that part or all of the sequence of the donor polynucleotide is incorporated into the target polynucleotide.

[0071] In the methods of the disclosure, one or more targeted nucleases as
20 described herein create a double-stranded break in the target sequence (*e.g.*, cellular chromatin) at a predetermined site, and a "donor" polynucleotide, having homology to the nucleotide sequence in the region of the break, can be introduced into the cell.

The presence of the double-stranded break has been shown to facilitate integration of the donor sequence. The donor sequence may be physically integrated or,
25 alternatively, the donor polynucleotide is used as a template for repair of the break via homologous recombination, resulting in the introduction of all or part of the nucleotide sequence as in the donor into the cellular chromatin. Thus, a first sequence in cellular chromatin can be altered and, in certain embodiments, can be converted into a sequence present in a donor polynucleotide. Thus, the use of the terms
30 "replace" or "replacement" can be understood to represent replacement of one nucleotide sequence by another, (*i.e.*, replacement of a sequence in the informational sense), and does not necessarily require physical or chemical replacement of one polynucleotide by another.

[0072] In any of the methods described herein, additional pairs of zinc-finger proteins can be used for additional double-stranded cleavage of additional target sites within the cell.

[0073] In certain embodiments of methods for targeted recombination and/or replacement and/or alteration of a sequence in a region of interest in cellular chromatin, a chromosomal sequence is altered by homologous recombination with an exogenous “donor” nucleotide sequence. Such homologous recombination is stimulated by the presence of a double-stranded break in cellular chromatin, if sequences homologous to the region of the break are present.

[0074] In any of the methods described herein, the first nucleotide sequence (the “donor sequence”) can contain sequences that are homologous, but not identical, to genomic sequences in the region of interest, thereby stimulating homologous recombination to insert a non-identical sequence in the region of interest. Thus, in certain embodiments, portions of the donor sequence that are homologous to sequences in the region of interest exhibit between about 80 to 99% (or any integer therebetween) sequence identity to the genomic sequence that is replaced. In other embodiments, the homology between the donor and genomic sequence is higher than 99%, for example if only 1 nucleotide differs as between donor and genomic sequences of over 100 contiguous base pairs. In certain cases, a non-homologous portion of the donor sequence can contain sequences not present in the region of interest, such that new sequences are introduced into the region of interest. In these instances, the non-homologous sequence is generally flanked by sequences of 50-1,000 base pairs (or any integral value therebetween) or any number of base pairs greater than 1,000, that are homologous or identical to sequences in the region of interest. In other embodiments, the donor sequence is non-homologous to the first sequence, and is inserted into the genome by non-homologous recombination mechanisms.

[0075] Any of the methods described herein can be used for partial or complete inactivation of one or more target sequences in a cell by targeted integration of donor sequence that disrupts expression of the gene(s) of interest. Cell lines with partially or completely inactivated genes are also provided.

[0076] Furthermore, the methods of targeted integration as described herein can also be used to integrate one or more exogenous sequences. The exogenous nucleic acid sequence can comprise, for example, one or more genes or cDNA

molecules, or any type of coding or noncoding sequence, as well as one or more control elements (e.g., promoters). In addition, the exogenous nucleic acid sequence may produce one or more RNA molecules (e.g., small hairpin RNAs (shRNAs), inhibitory RNAs (RNAis), microRNAs (miRNAs), etc.).

5 [0077] "Cleavage" refers to the breakage of the covalent backbone of a DNA molecule. Cleavage can be initiated by a variety of methods including, but not limited to, enzymatic or chemical hydrolysis of a phosphodiester bond. Both single-stranded cleavage and double-stranded cleavage are possible, and double-stranded cleavage can occur as a result of two distinct single-stranded cleavage events. DNA cleavage
10 can result in the production of either blunt ends or staggered ends. In certain embodiments, fusion polypeptides are used for targeted double-stranded DNA cleavage.

15 [0078] A "cleavage half-domain" is a polypeptide sequence which, in conjunction with a second polypeptide (either identical or different) forms a complex having cleavage activity (preferably double-strand cleavage activity). The terms "first and second cleavage half-domains;" "+ and – cleavage half-domains" and "right and left cleavage half-domains" are used interchangeably to refer to pairs of cleavage half-domains that dimerize.

20 [0079] An "engineered cleavage half-domain" is a cleavage half-domain that has been modified so as to form obligate heterodimers with another cleavage half-domain (e.g., another engineered cleavage half-domain). *See, also,* U.S. Patent Publication Nos. 2005/0064474, 20070218528 and 2008/0131962.

25 [0080] The term "sequence" refers to a nucleotide sequence of any length, which can be DNA or RNA; can be linear, circular or branched and can be either single-stranded or double stranded. The term "donor sequence" refers to a nucleotide sequence that is inserted into a genome. A donor sequence can be of any length, for example between 2 and 10,000 nucleotides in length (or any integer value therebetween or thereabove), preferably between about 100 and 1,000 nucleotides in length (or any integer therebetween), more preferably between about 200 and 500
30 nucleotides in length.

[0081] "Chromatin" is the nucleoprotein structure comprising the cellular genome. Cellular chromatin comprises nucleic acid, primarily DNA, and protein, including histones and non-histone chromosomal proteins. The majority of

eukaryotic cellular chromatin exists in the form of nucleosomes, wherein a nucleosome core comprises approximately 150 base pairs of DNA associated with an octamer comprising two each of histones H2A, H2B, H3 and H4; and linker DNA (of variable length depending on the organism) extends between nucleosome cores. A 5 molecule of histone H1 is generally associated with the linker DNA. For the purposes of the present disclosure, the term "chromatin" is meant to encompass all types of cellular nucleoprotein, both prokaryotic and eukaryotic. Cellular chromatin includes both chromosomal and episomal chromatin.

[0082] A "chromosome," is a chromatin complex comprising all or a portion 10 of the genome of a cell. The genome of a cell is often characterized by its karyotype, which is the collection of all the chromosomes that comprise the genome of the cell. The genome of a cell can comprise one or more chromosomes.

[0083] An "episome" is a replicating nucleic acid, nucleoprotein complex or 15 other structure comprising a nucleic acid that is not part of the chromosomal karyotype of a cell. Examples of episomes include plasmids and certain viral genomes.

[0084] A "target site" or "target sequence" is a nucleic acid sequence that defines a portion of a nucleic acid to which a binding molecule will bind, provided sufficient conditions for binding exist. For example, the sequence 5' GAATTC 3' is a 20 target site for the Eco RI restriction endonuclease. Exemplary target sites for various targeted ZFPs are shown in Table 2.

[0085] An "exogenous" molecule is a molecule that is not normally present in a cell, but can be introduced into a cell by one or more genetic, biochemical or other methods. "Normal presence in the cell" is determined with respect to the particular 25 developmental stage and environmental conditions of the cell. Thus, for example, a molecule that is present only during embryonic development of muscle is an exogenous molecule with respect to an adult muscle cell. Similarly, a molecule induced by heat shock is an exogenous molecule with respect to a non-heat-shocked cell. An exogenous molecule can comprise, for example, a functioning version of a 30 malfunctioning endogenous molecule or a malfunctioning version of a normally-functioning endogenous molecule.

[0086] An exogenous molecule can be, among other things, a small molecule, such as is generated by a combinatorial chemistry process, or a macromolecule such as a protein, nucleic acid, carbohydrate, lipid, glycoprotein, lipoprotein,

polysaccharide, any modified derivative of the above molecules, or any complex comprising one or more of the above molecules. Nucleic acids include DNA and RNA, can be single- or double-stranded; can be linear, branched or circular; and can be of any length. Nucleic acids include those capable of forming duplexes, as well as 5 triplex-forming nucleic acids. See, for example, U.S. Patent Nos. 5,176,996 and 5,422,251. Proteins include, but are not limited to, DNA-binding proteins, transcription factors, chromatin remodeling factors, methylated DNA binding proteins, polymerases, methylases, demethylases, acetylases, deacetylases, kinases, phosphatases, integrases, recombinases, ligases, topoisomerases, gyrases and 10 helicases.

10 [0087] An exogenous molecule can be the same type of molecule as an endogenous molecule, *e.g.*, an exogenous protein or nucleic acid. For example, an exogenous nucleic acid can comprise an infecting viral genome, a plasmid or episome introduced into a cell, or a chromosome that is not normally present in the cell. 15 Methods for the introduction of exogenous molecules into cells are known to those of skill in the art and include, but are not limited to, lipid-mediated transfer (*i.e.*, liposomes, including neutral and cationic lipids), electroporation, direct injection, cell fusion, particle bombardment, calcium phosphate co-precipitation, DEAE-dextran-mediated transfer and viral vector-mediated transfer. An exogenous molecule can also 20 be the same type of molecule as an endogenous molecule but derived from a different species than the cell is derived from. For example, a human nucleic acid sequence may be introduced into a cell line originally derived from a mouse or hamster.

20 [0088] By contrast, an "endogenous" molecule is one that is normally present in a particular cell at a particular developmental stage under particular environmental 25 conditions. For example, an endogenous nucleic acid can comprise a chromosome, the genome of a mitochondrion, chloroplast or other organelle, or a naturally- occurring episomal nucleic acid. Additional endogenous molecules can include proteins, for example, transcription factors and enzymes.

30 [0089] A "fusion" molecule is a molecule in which two or more subunit molecules are linked, preferably covalently. The subunit molecules can be the same chemical type of molecule, or can be different chemical types of molecules. Examples of the first type of fusion molecule include, but are not limited to, fusion proteins (for example, a fusion between a ZFP DNA-binding domain and one or more activation domains) and fusion nucleic acids (for example, a nucleic acid encoding the

fusion protein described *supra*). Examples of the second type of fusion molecule include, but are not limited to, a fusion between a triplex-forming nucleic acid and a polypeptide, and a fusion between a minor groove binder and a nucleic acid.

[0090] Expression of a fusion protein in a cell can result from delivery of the

5 fusion protein to the cell or by delivery of a polynucleotide encoding the fusion protein to a cell, wherein the polynucleotide is transcribed, and the transcript is translated, to generate the fusion protein. Trans-splicing, polypeptide cleavage and polypeptide ligation can also be involved in expression of a protein in a cell. Methods for polynucleotide and polypeptide delivery to cells are presented elsewhere in this
10 disclosure.

[0091] A "gene," for the purposes of the present disclosure, includes a DNA

region encoding a gene product (see *infra*), as well as all DNA regions which regulate the production of the gene product, whether or not such regulatory sequences are adjacent to coding and/or transcribed sequences. Accordingly, a gene includes, but is
15 not necessarily limited to, promoter sequences, terminators, translational regulatory sequences such as ribosome binding sites and internal ribosome entry sites, enhancers, silencers, insulators, boundary elements, replication origins, matrix attachment sites and locus control regions.

[0092] "Gene expression" refers to the conversion of the information,

20 contained in a gene, into a gene product. A gene product can be the direct transcriptional product of a gene (e.g., mRNA, tRNA, rRNA, antisense RNA, ribozyme, structural RNA or any other type of RNA) or a protein produced by translation of an mRNA. Gene products also include RNAs which are modified, by processes such as capping, polyadenylation, methylation, and editing, and proteins
25 modified by, for example, methylation, acetylation, phosphorylation, ubiquitination, ADP-ribosylation, myristilation, and glycosylation.

[0093] "Modulation" of gene expression refers to a change in the activity of a gene. Modulation of expression can include, but is not limited to, gene activation and gene repression. Genome editing (e.g., cleavage, alteration, inactivation, random

30 mutation) can be used to modulate expression. Gene inactivation refers to any reduction in gene expression as compared to a cell that does not include a ZFP as described herein. Thus, gene inactivation may be partial or complete.

[0094] A "region of interest" is any region of cellular chromatin, such as, for example, a gene or a non-coding sequence within or adjacent to a gene, in which it is

desirable to bind an exogenous molecule. Binding can be for the purposes of targeted DNA cleavage and/or targeted recombination. A region of interest can be present in a chromosome, an episome, an organellar genome (*e.g.*, mitochondrial, chloroplast), or an infecting viral genome, for example. A region of interest can be within the coding region of a gene, within transcribed non-coding regions such as, for example, leader sequences, trailer sequences or introns, or within non-transcribed regions, either upstream or downstream of the coding region. A region of interest can be as small as a single nucleotide pair or up to 2,000 nucleotide pairs in length, or any integral value of nucleotide pairs.

10 [0095] "Eukaryotic" cells include, but are not limited to, fungal cells (such as yeast), plant cells, animal cells, mammalian cells and human cells (*e.g.*, T-cells).

[0096] The terms "operative linkage" and "operatively linked" (or "operably linked") are used interchangeably with reference to a juxtaposition of two or more components (such as sequence elements), in which the components are arranged such 15 that both components function normally and allow the possibility that at least one of the components can mediate a function that is exerted upon at least one of the other components. By way of illustration, a transcriptional regulatory sequence, such as a promoter, is operatively linked to a coding sequence if the transcriptional regulatory sequence controls the level of transcription of the coding sequence in response to the 20 presence or absence of one or more transcriptional regulatory factors. A transcriptional regulatory sequence is generally operatively linked in *cis* with a coding sequence, but need not be directly adjacent to it. For example, an enhancer is a transcriptional regulatory sequence that is operatively linked to a coding sequence, even though they are not contiguous.

25 [0097] With respect to fusion polypeptides, the term "operatively linked" can refer to the fact that each of the components performs the same function in linkage to the other component as it would if it were not so linked. For example, with respect to a fusion polypeptide in which a ZFP DNA-binding domain is fused to an activation domain, the ZFP DNA-binding domain and the activation domain are in operative linkage if, in the fusion polypeptide, the ZFP DNA-binding domain portion is able to bind its target site and/or its binding site, while the activation domain is able to up-regulate gene expression. When a fusion polypeptide in which a ZFP DNA-binding domain is fused to a cleavage domain, the ZFP DNA-binding domain and the cleavage domain are in operative linkage if, in the fusion polypeptide, the ZFP DNA-

binding domain portion is able to bind its target site and/or its binding site, while the cleavage domain is able to cleave DNA in the vicinity of the target site.

[0098] A "functional fragment" of a protein, polypeptide or nucleic acid is a protein, polypeptide or nucleic acid whose sequence is not identical to the full-length protein, polypeptide or nucleic acid, yet retains the same function as the full-length protein, polypeptide or nucleic acid. A functional fragment can possess more, fewer, or the same number of residues as the corresponding native molecule, and/or can contain one or more amino acid or nucleotide substitutions. Methods for determining the function of a nucleic acid (e.g., coding function, ability to hybridize to another nucleic acid) are well-known in the art. Similarly, methods for determining protein function are well-known. For example, the DNA-binding function of a polypeptide can be determined, for example, by filter-binding, electrophoretic mobility-shift, or immunoprecipitation assays. DNA cleavage can be assayed by gel electrophoresis. See Ausubel *et al.*, *supra*. The ability of a protein to interact with another protein can be determined, for example, by co-immunoprecipitation, two-hybrid assays or complementation, both genetic and biochemical. See, for example, Fields *et al.* (1989) *Nature* 340:245-246; U.S. Patent No. 5,585,245 and PCT WO 98/44350.

[0099] A "vector" is capable of transferring gene sequences to target cells. Typically, "vector construct," "expression vector," and "gene transfer vector," mean any nucleic acid construct capable of directing the expression of a gene of interest and which can transfer gene sequences to target cells. Thus, the term includes cloning, and expression vehicles, as well as integrating vectors.

[0100] A "reporter gene" or "reporter sequence" refers to any sequence that produces a protein product that is easily measured, preferably although not necessarily in a routine assay. Suitable reporter genes include, but are not limited to, sequences encoding proteins that mediate antibiotic resistance (e.g., ampicillin resistance, 5 neomycin resistance, G418 resistance, puromycin resistance), sequences encoding colored or fluorescent or luminescent proteins (e.g., green fluorescent protein, enhanced green fluorescent protein, red fluorescent protein, luciferase), and proteins which mediate enhanced cell growth and/or gene amplification (e.g., dihydrofolate 10 reductase). Epitope tags include, for example, one or more copies of FLAG, His, myc, Tap, HA or any detectable amino acid sequence. "Expression tags" include sequences that encode reporters that may be operably linked to a desired gene sequence in order to monitor expression of the gene of interest.

DNA-binding domains

[0101] Described herein are compositions comprising a DNA-binding domain that specifically bind to a target site in any gene comprising a HLA gene or a HLA regulator. Any DNA-binding domain can be used in the compositions and methods disclosed herein.

[0102] In certain embodiments, the DNA binding domain comprises a zinc finger protein. Preferably, the zinc finger protein is non-naturally occurring in that it is engineered to bind to a target site of choice. *See*, for example, Beerli *et al.* (2002) *Nature Biotechnol.* **20**:135-141; Pabo *et al.* (2001) *Ann. Rev. Biochem.* **70**:313-340; Isalan *et al.* (2001) *Nature Biotechnol.* **19**:656-660; Segal *et al.* (2001) *Curr. Opin. Biotechnol.* **12**:632-637; Choo *et al.* (2000) *Curr. Opin. Struct. Biol.* **10**:411-416; U.S. 20 Patent Nos. 6,453,242; 6,534,261; 6,599,692; 6,503,717; 6,689,558; 7,030,215; 6,794,136; 7,067,317; 7,262,054; 7,070,934; 7,361,635; 7,253,273; and U.S. Patent Publication Nos. 2005/0064474; 2007/0218528; 2005/0267061.

[0103] Engineered zinc finger binding domain can have a novel binding specificity, compared to a naturally-occurring zinc finger protein. Engineering 30 methods include, but are not limited to, rational design and various types of selection. Rational design includes, for example, using databases comprising triplet (or quadruplet) nucleotide sequences and individual zinc finger amino acid sequences, in which each triplet or quadruplet nucleotide sequence is associated with one or more

amino acid sequences of zinc fingers which bind the particular triplet or quadruplet sequence. See, for example, co-owned U.S. Patents 6,453,242 and 6,534,261.

[0104] Exemplary selection methods, including phage display and two-hybrid systems, are disclosed in US Patents 5,789,538; 5,925,523; 6,007,988; 6,013,453; 5 6,410,248; 6,140,466; 6,200,759; and 6,242,568; as well as WO 98/37186; WO 98/53057; WO 00/27878; WO 01/88197 and GB 2,338,237. In addition, enhancement of binding specificity for zinc finger binding domains has been described, for example, in co-owned WO 02/077227.

[0105] In addition, as disclosed in these and other references, zinc finger 10 domains and/or multi-fingered zinc finger proteins may be linked together using any suitable linker sequences, including for example, linkers of 5 or more amino acids in length. See, also, U.S. Patent Nos. 6,479,626; 6,903,185; and 7,153,949 for exemplary linker sequences 6 or more amino acids in length. The proteins described herein may include any combination of suitable linkers between the individual zinc 15 fingers of the protein. In addition, enhancement of binding specificity for zinc finger binding domains has been described, for example, in co-owned WO 02/077227.

[0106] Selection of target sites; ZFPs and methods for design and construction of fusion proteins (and polynucleotides encoding same) are known to those of skill in the art and described in detail in U.S. Patent Nos. 6,140,0815; 789,538; 6,453,242; 20 6,534,261; 5,925,523; 6,007,988; 6,013,453; 6,200,759; WO 95/19431; WO 96/06166; WO 98/53057; WO 98/54311; WO 00/27878; WO 01/60970 WO 01/88197; WO 02/099084; WO 98/53058; WO 98/53059; WO 98/53060; WO 02/016536 and WO 03/016496.

[0107] In addition, as disclosed in these and other references, zinc finger 25 domains and/or multi-fingered zinc finger proteins may be linked together using any suitable linker sequences, including for example, linkers of 5 or more amino acids in length. See, also, U.S. Patent Nos. 6,479,626; 6,903,185; and 7,153,949 for exemplary linker sequences 6 or more amino acids in length. The proteins described herein may include any combination of suitable linkers between the individual zinc 30 fingers of the protein.

[0108] Alternatively, the DNA-binding domain may be derived from a nuclease. For example, the recognition sequences of homing endonucleases and meganucleases such as I-SceI, I-CeuI, PI-PspI, PI-Sce, I-SceIV, I-CsmI, I-PanI, I-SceII, I-PpoI, I-SceIII, I-CreI, I-TevI, I-TevII and I-TevIII are known. See also U.S.

Patent No. 5,420,032; U.S. Patent No. 6,833,252; Belfort *et al.* (1997) *Nucleic Acids Res.* **25**:3379–3388; Dujon *et al.* (1989) *Gene* **82**:115–118; Perler *et al.* (1994) *Nucleic Acids Res.* **22**, 1125–1127; Jasins (1996) *Trends Genet.* **12**:224–228; Gimble *et al.* (1996) *J. Mol. Biol.* **263**:163–180; Argast *et al.* (1998) *J. Mol. Biol.* **280**:345–353 and the New England Biolabs catalogue. In addition, the DNA-binding specificity of homing endonucleases and meganucleases can be engineered to bind non-natural target sites. *See, for example, Chevalier *et al.* (2002) Molec. Cell* **10**:895–905; Epinat *et al.* (2003) *Nucleic Acids Res.* **31**:2952-2962; Ashworth *et al.* (2006) *Nature* **441**:656-659; Paques *et al.* (2007) *Current Gene Therapy* **7**:49-66; U.S. Patent Publication No. 20070117128.

[0109] In certain embodiments, the DNA binding domain is an engineered zinc finger protein that binds (in a sequence-specific manner) to a target site in a HLA gene or HLA regulatory gene and modulates expression of HLA. The ZFPs can bind selectively to a specific haplotype of interest. For a discussion of HLA haplotypes identified in the United States population and their frequency according to different races, see Maiers *et al* (2007) *Human Immunology* **68**: 779- 788. Additionally, ZFPs are provided that bind to functional HLA regulator genes including, but not limited to, Tap1, Tap2, Tapascin, CTFIIA, and RFX5. HLA target sites typically include at least one zinc finger but can include a plurality of zinc fingers (e.g., 2, 3, 4, 5, 6 or more fingers). Usually, the ZFPs include at least three fingers. Certain of the ZFPs include four, five or six fingers. The ZFPs that include three fingers typically recognize a target site that includes 9 or 10 nucleotides; ZFPs that include four fingers typically recognize a target site that includes 12 to 14 nucleotides; while ZFPs having six fingers can recognize target sites that include 18 to 21 nucleotides. The ZFPs can also be fusion proteins that include one or more regulatory domains, which domains can be transcriptional activation or repression domains.

[0110] Specific examples of targeted ZFPs are disclosed in Table 1. The first column in this table is an internal reference name (number) for a ZFP and corresponds to the same name in column 1 of Table 2. “F” refers to the finger and the number following “F” refers which zinc finger (e.g., “F1” refers to finger 1).

Table 1: Zinc finger proteins

| Target | SBS # | Design | | | | | |
|-------------------|-------|------------------------------|------------------------------|------------------------------|------------------------------|-------------------------------|------------------------------|
| Class I | | F1 | F2 | F3 | F4 | F5 | F6 |
| HLA A2 | 18889 | QSSHLTR (SEQ ID NO:1) | RSDHLTT (SEQ ID NO:2) | RSDTLSQ (SEQ ID NO:3) | RSADLSR (SEQ ID NO:4) | QSSDLQR (SEQ ID NO:5) | RSDALTQ (SEQ ID NO:6) |
| HLA A2 | 18881 | QKTHLAK (SEQ ID NO:7) | RSDTLSN (SEQ ID NO:8) | RKDVRIT (SEQ ID NO:9) | RSDHLST (SEQ ID NO:10) | DSSARKK (SEQ ID NO:11) | NA |
| HLA A2 | 24859 | QNAHRKT (SEQ ID NO:12) | RSDSLRR (SEQ ID NO:13) | RNDDRKK (SEQ ID NO:14) | RSDHLST (SEQ ID NO:10) | DSSARKK (SEQ ID NO:11) | NA |
| HLA A3 | 25191 | DRSHLSR (SEQ ID NO:15) | RSDDLTR (SEQ ID NO:16) | DRSDLQR (SEQ ID NO:17) | QSGHLSR (SEQ ID NO:18) | NA | NA |
| HLA A3 | 25190 | DRSALSR (SEQ ID NO:19) | QSSDLRR (SEQ ID NO:20) | DRSALSR (SEQ ID NO:19) | DRSHLAR (SEQ ID NO:21) | RSDDLSK (SEQ ID NO:22) | DRSHLAR (SEQ ID NO:21) |
| HLA B | 25316 | SSELLNE (SEQ ID NO:23) | TSSHLSR (SEQ ID NO:24) | QSGDRNK (SEQ ID NO:25) | RSANLAR (SEQ ID NO:26) | RSNLRLRE (SEQ ID NO:27) | NA |
| HLA B | 25317 | QSGDLTR (SEQ ID NO:28) | RSDDLTR (SEQ ID NO:16) | DQSTLRN (SEQ ID NO:29) | DRSNLSR (SEQ ID NO:30) | DAFTRTR (SEQ ID NO:31) | NA |
| HLA B-up | 15267 | RSNLSE (SEQ ID NO:32) | ASKTRKN (SEQ ID NO:33) | TSGNLTR (SEQ ID NO:34) | RSDALAR (SEQ ID NO:35) | NA | NA |
| HLA B-up | 15265 | DRSALSR (SEQ ID NO:19) | QSGNLAR (SEQ ID NO:36) | DRSALSR (SEQ ID NO:19) | QSGHLSR (SEQ ID NO:18) | NA | NA |
| HLA B-up | 17454 | RSNLSE (SEQ ID NO:32) | ASKTRKN (SEQ ID NO:33) | QSGHLSR (SEQ ID NO:18) | TSGHLSR (SEQ ID NO:37) | QSGHLSR (SEQ ID NO:18) | NA |
| HLA B-up | 17456 | RSADLTR (SEQ ID NO:38) | QSGDLTR (SEQ ID NO:28) | QSGNLAR (SEQ ID NO:36) | QSGDLTR (SEQ ID NO:28) | NA | NA |
| HLA C-down | 15296 | QSGHLSR (SEQ ID NO:18) | RSDHLST (SEQ ID NO:10) | QSADRTK (SEQ ID NO:39) | TSGSLSR (SEQ ID NO:40) | QSADRTK (SEQ ID NO:39) | NA |
| HLA C-down | 15298 | QSGDLTR (SEQ ID NO:28) | RSDHLST (SEQ ID NO:10) | QSADRTK (SEQ ID NO:39) | RSNLSA (SEQ ID NO:41) | RSDNRTT (SEQ ID NO:42) | NA |
| HLA C | 25588 | QRSNLVR (SEQ ID NO:43) | DRSALAR (SEQ ID NO:44) | QSSDLRR (SEQ ID NO:20) | RSDDLTR (SEQ ID NO:16) | RSDDLTR (SEQ ID NO:16) | NA |
| HLA C | 25589 | RSDDLTR (SEQ ID NO:16) | DRSALSR (SEQ ID NO:17) | QSGHLSR (SEQ ID NO:18) | RSDHLSA (SEQ ID NO:45) | ESRYLMV (SEQ ID NO:46) | NA |
| Class II | | | | | | | |
| DBP2-up | 15872 | RSDHLST (SEQ ID NO:10) | DNANRTK (SEQ ID NO:47) | QSGDLTR (SEQ ID NO:28) | RSDALST (SEQ ID NO:48) | ASSNRKT (SEQ ID NO:49) | NA |
| DBP2-up | 15873 | TSGNLTR (SEQ ID NO:34) | DRSALSR (SEQ ID NO:17) | RSNLSE (SEQ ID NO:32) | RSANLTR (SEQ ID NO:50) | QSGHLSR (SEQ ID NO:18) | NA |
| DRA-down | 15909 | RSNLSE (SEQ ID | TSGSLTR (SEQ ID | TSGHLSR (SEQ ID | RSDNLSQ (SEQ ID | ASNDRKK (SEQ ID | NA |

| | | | | | | | |
|----------|-------|------------------------------|------------------------------|-------------------------------|------------------------------|------------------------------|----|
| | | NO:32) | NO:51) | NO:37) | NO:52) | NO:53) | |
| DRA-down | 15910 | RSDNLSR (SEQ ID NO:54) | DNNARIN (SEQ ID NO:55) | RSDSL SV (SEQ ID NO:56) | QNQHRIN (SEQ ID NO:57) | RSDHLSR (SEQ ID NO:58) | NA |

| Regulators | | | | | | | |
|----------------|-------|------------------------------|------------------------------|------------------------------|------------------------------|------------------------------|------------------------------|
| TAP1 | 28386 | DSSDRKK (SEQ ID NO:59) | DRSHLTR (SEQ ID NO:60) | RSDALAR (SEQ ID NO:35) | QSSDLSE (SEQ ID NO:5) | RSDNLTT (SEQ ID NO:61) | NA |
| TAP1 | 28385 | RSANLAR (SEQ ID NO:26) | QSGHLSR (SEQ ID NO:18) | TSGNLTR (SEQ ID NO:34) | QSGALVI (SEQ ID NO:62) | RSDHLSE (SEQ ID NO:63) | RKHDRTK (SEQ ID NO:64) |
| TAP2 | 28394 | QSSDLSE (SEQ ID NO:5) | QSGDLTR (SEQ ID NO:28) | QSSHLTR (SEQ ID NO:1) | RSDDRKT (SEQ ID NO:65) | TSGNLTR (SEQ ID NO:34) | RSDDLTR (SEQ ID NO:16) |
| TAP2 | 28393 | RSDNLST (SEQ ID NO:66) | RSDALAR (SEQ ID NO:35) | RSDVLSA (SEQ ID NO:67) | DRSNRIK (SEQ ID NO:68) | RREDLIT (SEQ ID NO:69) | TSSNLSR (SEQ ID NO:70) |
| Tapasin | 28406 | RSDNLSE (SEQ ID NO:32) | KRCNLRC (SEQ ID NO:71) | DRSDLSE (SEQ ID NO:17) | QTTHRNR (SEQ ID NO:72) | DRSDLSE (SEQ ID NO:17) | QSSTRAR (SEQ ID NO:73) |
| Tapasin | 28405 | QSSDLSE (SEQ ID NO:5) | RSDNLTR (SEQ ID NO:74) | QSSHLTR (SEQ ID NO:1) | QSSDLTR (SEQ ID NO:75) | RSDNLAR (SEQ ID NO:76) | QKVNLMS (SEQ ID NO:77) |
| Tapasin | 28404 | TSGNLTR (SEQ ID NO:34) | LSQDLNR (SEQ ID NO:78) | RSDSLSA (SEQ ID NO:79) | DRSHLAR (SEQ ID NO:21) | RSDHLST (SEQ ID NO:10) | QSGHLSR (SEQ ID NO:18) |
| Tapasin | 28403 | RSDDLTR (SEQ ID NO:16) | SSSNLTK (SEQ ID NO:80) | TSGSLSR (SEQ ID NO:40) | QSGDLTR (SEQ ID NO:28) | RSDHLSE (SEQ ID NO:63) | RNRDRIT (SEQ ID NO:81) |
| CTIIA | 15486 | RSDDLTR (SEQ ID NO:16) | RSDHLSE (SEQ ID NO:63) | NSRNRKT (SEQ ID NO:82) | RSDNLSE (SEQ ID NO:52) | ASNDRKK (SEQ ID NO:53) | NA |
| CTIIA | 15487 | RSDDLSE (SEQ ID NO:83) | RNDDRKK (SEQ ID NO:14) | DRSDLSE (SEQ ID NO:17) | RSDHLSE (SEQ ID NO:63) | ARSTRTN (SEQ ID NO:84) | NA |
| RFX5 | 15506 | TSGNLTR (SEQ ID NO:34) | QSGNLAR (SEQ ID NO:36) | RSDHLTQ (SEQ ID NO:85) | ASMALNE (SEQ ID NO:86) | TSSNLSR (SEQ ID NO:70) | NA |
| RFX5 | 15507 | RSDVLSE (SEQ ID NO:87) | RNQHRKT (SEQ ID NO:88) | RSDHLST (SEQ ID NO:10) | QSSDLRR (SEQ ID NO:20) | RSDNLST (SEQ ID NO:66) | RSADRKN (SEQ ID NO:89) |
| Others | | | | | | | |
| TRAC | 25539 | QSGDLTR (SEQ ID NO:28) | QWGTRYR (SEQ ID NO:90) | ERGTLAR (SEQ ID NO:91) | RSDNLRE (SEQ ID NO:27) | QSGDLTR (SEQ ID NO:28) | TSGSLTR (SEQ ID NO:51) |
| TRAC | 25540 | QSGDLTR (SEQ ID NO:28) | WRSSLAS (SEQ ID NO:92) | QSGDLTR (SEQ ID NO:28) | HKWVLRQ (SEQ ID NO:93) | RDSNLTR (SEQ ID NO:94) | NA |
| TRBC | 16783 | RSDVLSA (SEQ ID NO:67) | DRSNRIK (SEQ ID NO:68) | RSDVLSE (SEQ ID NO:87) | QSGNLAR (SEQ ID NO:36) | QSGSLTR (SEQ ID NO:95) | NA |
| TRBC | 16787 | RSDHLST (SEQ ID NO:10) | RSDNLTR (SEQ ID NO:74) | RDSNLSE (SEQ ID NO:30) | TSSNRKT (SEQ ID NO:96) | RSANLAR (SEQ ID NO:26) | RNDDRKK (SEQ ID NO:14) |

[0111] The sequence for the target sites of these proteins are disclosed in

Table 2. Table 2 shows target sequences for the indicated zinc finger proteins.

5 Nucleotides in the target site that are contacted by the ZFP recognition helices are indicated in uppercase letters; non-contacted nucleotides indicated in lowercase.

Table 2: Zinc finger target sites

| Target | SBS # | Target site |
|-------------------|-------|------------------------------------------------|
| Class I | | |
| HLA A2 | 18889 | gtATGGCTGCGACGTGGGGTcggacggg_(SEQ ID NO:97) |
| HLA A2 | 18881 | ttATCTGGATGGTGTGAGaacctggccc_(SEQ ID NO:98) |
| HLA A2 | 24859 | tctCTGGACGGTGTGAGaacctggccc_(SEQ ID NO:99) |
| HLA A3 | 25191 | atGGAGCCGCGGGCgcgtggatagagc_(SEQ ID NO:100) |
| HLA A3 | 25190 | ctGGCTCGcGGCGTCGCTGTCgaaccgc_(SEQ ID NO:101) |
| HLA B-up | 25316 | tcCAGGAGcTCAGGTCCtcgttcaggc_(SEQ ID NO:102) |
| HLA B-up | 25317 | cgCGGGACACCGCGGGCtcagatcacca_(SEQ ID NO:103) |
| HLA B-up | 15267 | agGTGGATGCCAGgacgagcttgagg_(SEQ ID NO:104) |
| HLA B-up | 15265 | agGGAGCAGAACGAgcgcagcgcacca_(SEQ ID NO:105) |
| HLA B-up | 17454 | ctGGGAGGTGGAAtGCCAGgacgagcttt_(SEQ ID NO:106) |
| HLA B-up | 17456 | gaGCAGAACGAGCAGCgcagcgcaccc_(SEQ ID NO:107) |
| HLA C-down | 15296 | cctCAGTTTCAATGGGGAttcaaggaaac_(SEQ ID NO:108) |
| HLA C-down | 15298 | ccTAGGAGgTCATGGGCATttgcattgc_(SEQ ID NO:109) |
| HLA C-down | 25588 | tcGGGGCGtccGCTGTCGAAccgcaccaa_(SEQ ID NO:110) |
| HLA C-down | 25589 | ccaAGAGGGGAGCCGCCGggagccgtggg_(SEQ ID NO:111) |
| Class II | | |
| DPB2-up | 15872 | gaAATAAGGCATACTGGtattactaatg_(SEQ ID NO:112) |
| DPB2-up | 15873 | gaGGAGAGCAGGGCCGATtacctgaccca_(SEQ ID NO:113) |
| DRA-down | 15909 | tcTCCCAGGGTgGTTCAggtggcagaatt_(SEQ ID NO:114) |
| DRA-down | 15910 | gcGGGGGAAAGaGAGGAGgagagaagga_(SEQ ID NO:115) |
| Regulators | | |
| TAP1 | 28386 | agaAGGGCTGGGGCTCCtcaagagaaaat_(SEQ ID NO:116) |
| TAP1 | 28385 | actCTGGGGTAGATGGAGAGcagtaccc_(SEQ ID NO:117) |
| TAP2 | 28394 | ttGGGGATCCGGGAGCAGCTttctcct_(SEQ ID NO:118) |
| TAP2 | 28393 | ttGATTCGaGACATGGTGTAGgtgaagc_(SEQ ID NO:119) |
| Tapasin | 28406 | ccACAGCCAGAGCCTcAGCAGgagcctg_(SEQ ID NO:120) |
| Tapasin | 28405 | cgCAAGAGGCTGGAGAGGCTgaggactg_(SEQ ID NO:121) |
| Tapasin | 28404 | ctGGATGGGGCTTGGCTGATggtcagca_(SEQ ID NO:122) |
| Tapasin | 28403 | gcCCGGGGCAGTTcTGGCGGgggtca_(SEQ ID NO:123) |
| CTIIA | 15486 | gcTCCCAGgCAGCGGGCggaggctgga_(SEQ ID NO:124) |
| CTIIA | 15487 | ctACTCGGGCCaTCGGCGctgcctcg_(SEQ ID NO:125) |
| RFX5 | 15506 | ttGATGTCAGGGAAAGATctctctgatga_(SEQ ID NO:126) |
| RFX5 | 15507 | gcTCGAAGGCTTGGTGGCCGggccagt_(SEQ ID NO:127) |
| Others | | |
| TRAC | 25539 | ttGTTGCTcCAGGCCACAGCActgttgc_(SEQ ID NO:128) |
| TRAC | 25540 | ctGACTTTGCATGTGCAaacgccttcaa_(SEQ ID NO:129) |
| TRBC | 16783 | ccGTAGAACTGGACTTGCacagcggaaagt_(SEQ ID NO:130) |
| TRBC | 16787 | tcTCGGAGAATGACGAGTGGacccagga_(SEQ ID NO:131) |

[0112] In some embodiments, the DNA binding domain is an engineered domain from a TAL effector similar to those derived from the plant pathogens *Xanthomonas* (see Boch *et al*, (2009) *Science* 326: 1509-1512 and Moscou and

Bogdanove, (2009) *Science* 326: 1501) and Ralstonia (see Heuer *et al* (2007) *Applied and Environmental Microbiology* 73(13): 4379-4384); U.S. Patent Application No. 13/068,735 and U.S. Patent Publication No. 20110145940

5 **Fusion proteins**

[0113] Fusion proteins comprising DNA-binding proteins (*e.g.*, ZFPs or TALEs) as described herein and a heterologous regulatory (functional) domain (or functional fragment thereof) are also provided. Common domains include, *e.g.*, transcription factor domains (activators, repressors, co-activators, co-repressors), 10 silencers, oncogenes (*e.g.*, myc, jun, fos, myb, max, mad, rel, ets, bcl, myb, mos family members etc.); DNA repair enzymes and their associated factors and modifiers; DNA rearrangement enzymes and their associated factors and modifiers; chromatin associated proteins and their modifiers (*e.g.* kinases, acetylases and deacetylases); and DNA modifying enzymes (*e.g.*, methyltransferases, 15 topoisomerases, helicases, ligases, kinases, phosphatases, polymerases, endonucleases) and their associated factors and modifiers. U.S. Patent Application Publication Nos. 20050064474; 20060188987 and 2007/0218528 for details regarding fusions of DNA-binding domains and nuclease cleavage domains.

[0114] Suitable domains for achieving activation include the HSV VP16 20 activation domain (*see, e.g.*, Hagmann *et al.*, *J. Virol.* 71, 5952-5962 (1997)) nuclear hormone receptors (*see, e.g.*, Torchia *et al.*, *Curr. Opin. Cell. Biol.* 10:373-383 (1998)); the p65 subunit of nuclear factor kappa B (Bitko & Barik, *J. Virol.* 72:5610-5618 (1998) and Doyle & Hunt, *Neuroreport* 8:2937-2942 (1997)); Liu *et al.*, *Cancer Gene Ther.* 5:3-28 (1998)), or artificial chimeric functional domains such as VP64 25 (Beerli *et al.*, (1998) *Proc. Natl. Acad. Sci. USA* 95:14623-33), and degron (Molinari *et al.*, (1999) *EMBO J.* 18, 6439-6447). Additional exemplary activation domains include, Oct 1, Oct-2A, Sp1, AP-2, and CTF1 (Seipel *et al.*, *EMBO J.* 11, 4961-4968 (1992) as well as p300, CBP, PCAF, SRC1 PvALF, AtHD2A and ERF-2. *See, for example*, Robyr *et al.* (2000) *Mol. Endocrinol.* 14:329-347; Collingwood *et al.* (1999) 30 *J. Mol. Endocrinol.* 23:255-275; Leo *et al.* (2000) *Gene* 245:1-11; Manteuffel-Cymborowska (1999) *Acta Biochim. Pol.* 46:77-89; McKenna *et al.* (1999) *J. Steroid Biochem. Mol. Biol.* 69:3-12; Malik *et al.* (2000) *Trends Biochem. Sci.* 25:277-283; and Lemon *et al.* (1999) *Curr. Opin. Genet. Dev.* 9:499-504. Additional exemplary

activation domains include, but are not limited to, OsGAI, HALF-1, C1, AP1, ARF-5,-6,-7, and -8, CPRF1, CPRF4, MYC-RP/GP, and TRAB1. *See, for example, Ogawa et al. (2000) Gene 245:21-29; Okanami et al. (1996) Genes Cells 1:87-99; Goff et al. (1991) Genes Dev. 5:298-309; Cho et al. (1999) Plant Mol. Biol. 40:419-429;*

5 *Ulmason et al. (1999) Proc. Natl. Acad. Sci. USA 96:5844-5849; Sprenger-Haussels et al. (2000) Plant J. 22:1-8; Gong et al. (1999) Plant Mol. Biol. 41:33-44; and Hobo et al. (1999) Proc. Natl. Acad. Sci. USA 96:15,348-15,353.*

10 [0115] It will be clear to those of skill in the art that, in the formation of a fusion protein (or a nucleic acid encoding same) between a DNA-binding domain and a functional domain, either an activation domain or a molecule that interacts with an activation domain is suitable as a functional domain. Essentially any molecule capable of recruiting an activating complex and/or activating activity (such as, for example, histone acetylation) to the target gene is useful as an activating domain of a fusion protein. Insulator domains, localization domains, and chromatin remodeling 15 proteins such as ISWI-containing domains and/or methyl binding domain proteins suitable for use as functional domains in fusion molecules are described, for example, in co-owned U.S. Patent Applications 2002/0115215 and 2003/0082552 and in co-owned WO 02/44376.

20 [0116] Exemplary repression domains include, but are not limited to, KRAB A/B, KOX, TGF-beta-inducible early gene (TIEG), v-erbA, SID, MBD2, MBD3, members of the DNMT family (e.g., DNMT1, DNMT3A, DNMT3B), Rb, and MeCP2. *See, for example, Bird et al. (1999) Cell 99:451-454; Tyler et al. (1999) Cell 99:443-446; Knoepfler et al. (1999) Cell 99:447-450; and Robertson et al. (2000) Nature Genet. 25:338-342.* Additional exemplary repression domains include, but are 25 not limited to, ROM2 and AtHD2A. *See, for example, Chem et al. (1996) Plant Cell 8:305-321; and Wu et al. (2000) Plant J. 22:19-27.*

30 [0117] Fusion molecules are constructed by methods of cloning and biochemical conjugation that are well known to those of skill in the art. Fusion molecules comprise a DNA-binding domain and a functional domain (e.g., a transcriptional activation or repression domain). Fusion molecules also optionally comprise nuclear localization signals (such as, for example, that from the SV40 medium T-antigen) and epitope tags (such as, for example, FLAG and hemagglutinin). Fusion proteins (and nucleic acids encoding them) are designed such that the translational reading frame is preserved among the components of the fusion.

[0118] Fusions between a polypeptide component of a functional domain (or a functional fragment thereof) on the one hand, and a non-protein DNA-binding domain (e.g., antibiotic, intercalator, minor groove binder, nucleic acid) on the other, are constructed by methods of biochemical conjugation known to those of skill in the art.

5 *See, for example, the Pierce Chemical Company (Rockford, IL) Catalogue. Methods and compositions for making fusions between a minor groove binder and a polypeptide have been described. Mapp et al. (2000) Proc. Natl. Acad. Sci. USA 97:3930-3935.*

[0119] In certain embodiments, the target site bound by the zinc finger protein 10 is present in an accessible region of cellular chromatin. Accessible regions can be determined as described, for example, in co-owned International Publication WO 01/83732. If the target site is not present in an accessible region of cellular chromatin, one or more accessible regions can be generated as described in co-owned WO 01/83793. In additional embodiments, the DNA-binding domain of a fusion 15 molecule is capable of binding to cellular chromatin regardless of whether its target site is in an accessible region or not. For example, such DNA-binding domains are capable of binding to linker DNA and/or nucleosomal DNA. Examples of this type of "pioneer" DNA binding domain are found in certain steroid receptor and in hepatocyte nuclear factor 3 (HNF3). Cordingley et al. (1987) *Cell* 48:261-270; Pina et 20 al. (1990) *Cell* 60:719-731; and Cirillo et al. (1998) *EMBO J.* 17:244-254.

[0120] The fusion molecule may be formulated with a pharmaceutically acceptable carrier, as is known to those of skill in the art. *See, for example, Remington's Pharmaceutical Sciences*, 17th ed., 1985; and co-owned WO 00/42219.

[0121] The functional component/domain of a fusion molecule can be selected 25 from any of a variety of different components capable of influencing transcription of a gene once the fusion molecule binds to a target sequence via its DNA binding domain. Hence, the functional component can include, but is not limited to, various transcription factor domains, such as activators, repressors, co-activators, co-repressors, and silencers.

30 [0122] Additional exemplary functional domains are disclosed, for example, in co-owned US Patent No. 6,534,261 and US Patent Application Publication No. 2002/0160940.

[0123] Functional domains that are regulated by exogenous small molecules or ligands may also be selected. For example, RheoSwitch® technology may be

employed wherein a functional domain only assumes its active conformation in the presence of the external RheoChem™ ligand (see for example US 20090136465). Thus, the ZFP may be operably linked to the regulatable functional domain wherein the resultant activity of the ZFP-TF is controlled by the external ligand.

5

Nucleases

[0124] In certain embodiments, the fusion protein comprises a DNA-binding binding domain and cleavage (nuclease) domain. As such, gene modification can be achieved using a nuclease, for example an engineered nuclease. Engineered nuclease 10 technology is based on the engineering of naturally occurring DNA-binding proteins. For example, engineering of homing endonucleases with tailored DNA-binding specificities has been described. Chames *et al.* (2005) *Nucleic Acids Res* 33(20):e178; Arnould *et al.* (2006) *J. Mol. Biol.* 355:443-458. In addition, engineering of ZFPs has also been described. See, *e.g.*, U.S. Patent Nos. 6,534,261; 6,607,882; 6,824,978; 15 6,979,539; 6,933,113; 7,163,824; and 7,013,219.

[0125] In addition, ZFPs and/or TALEs have been fused to nuclease domains to create ZFNs and TALENs – a functional entity that is able to recognize its intended nucleic acid target through its engineered (ZFP or TALE) DNA binding domain and cause the DNA to be cut near the DNA binding site via the nuclease activity. See, 20 *e.g.*, Kim *et al.* (1996) *Proc Nat'l Acad Sci USA* 93(3):1156-1160. More recently, such nucleases have been used for genome modification in a variety of organisms. See, for example, United States Patent Publications 20030232410; 20050208489; 20050026157; 20050064474; 20060188987; 20060063231; and International Publication WO 07/014275.

[0126] Thus, the methods and compositions described herein are broadly applicable and may involve any nuclease of interest. Non-limiting examples of nucleases include meganucleases, TALENs and zinc finger nucleases. The nuclease may comprise heterologous DNA-binding and cleavage domains (*e.g.*, zinc finger nucleases; meganuclease DNA-binding domains with heterologous cleavage domains) 30 or, alternatively, the DNA-binding domain of a naturally-occurring nuclease may be altered to bind to a selected target site (*e.g.*, a meganuclease that has been engineered to bind to site different than the cognate binding site).

[0127] In certain embodiments, the nuclease is a meganuclease (homing endonuclease). Naturally-occurring meganucleases recognize 15-40 base-pair

cleavage sites and are commonly grouped into four families: the LAGLIDADG family, the GIY-YIG family, the His-Cyst box family and the HNH family.

Exemplary homing endonucleases include I-SceI, I-CeuI, PI-PspI, PI-Sce, I-SceIV, I-CsmI, I-PanI, I-SceII, I-PpoI, I-SceIII, I-CreI, I-TevI, I-TevII and I-TevIII. Their

5 recognition sequences are known. See also U.S. Patent No. 5,420,032; U.S. Patent No. 6,833,252; Belfort *et al.* (1997) *Nucleic Acids Res.* **25**:3379–3388; Dujon *et al.* (1989) *Gene* **82**:115–118; Perler *et al.* (1994) *Nucleic Acids Res.* **22**, 1125–1127; Jaslin (1996) *Trends Genet.* **12**:224–228; Gimble *et al.* (1996) *J. Mol. Biol.* **263**:163–180; Argast *et al.* (1998) *J. Mol. Biol.* **280**:345–353 and the New England Biolabs

10 catalogue.

[0128] DNA-binding domains from naturally-occurring meganucleases, primarily from the LAGLIDADG family, have been used to promote site-specific genome modification in plants, yeast, Drosophila, mammalian cells and mice, but this approach has been limited to the modification of either homologous genes that

15 conserve the meganuclease recognition sequence (Monet *et al.* (1999), *Biochem.*

Biophysics. Res. Common. **255**: 88-93) or to pre-engineered genomes into which a recognition sequence has been introduced (Route *et al.* (1994), *Mol. Cell. Biol.* **14**: 8096-106; Chilton *et al.* (2003), *Plant Physiology* **133**: 956-65; Puchta *et al.* (1996), *Proc. Natl. Acad. Sci. USA* **93**: 5055-60; Rong *et al.* (2002), *Genes Dev.* **16**: 1568-81;

20 Gouble *et al.* (2006), *J. Gene Med.* **8**(5):616-622). Accordingly, attempts have been made to engineer meganucleases to exhibit novel binding specificity at medically or biotechnologically relevant sites (Porteus *et al.* (2005), *Nat. Biotechnol.* **23**: 967-73; Sussman *et al.* (2004), *J. Mol. Biol.* **342**: 31-41; Epinat *et al.* (2003), *Nucleic Acids Res.* **31**: 2952-62; Chevalier *et al.* (2002) *Molec. Cell* **10**:895-905; Epinat *et al.* (2003)

25 *Nucleic Acids Res.* **31**:2952-2962; Ashworth *et al.* (2006) *Nature* **441**:656-659;

Paques *et al.* (2007) *Current Gene Therapy* **7**:49-66; U.S. Patent Publication Nos.

20070117128; 20060206949; 20060153826; 20060078552; and 20040002092). In

addition, naturally-occurring or engineered DNA-binding domains from

30 meganucleases have also been operably linked with a cleavage domain from a

heterologous nuclease (e.g., *FokI*).

[0129] In other embodiments, the nuclease is a zinc finger nuclease (ZFN) or TALE DNA binding domain-nuclease fusion (TALEN). ZFNs and TALENs comprise a DNA binding domain (zinc finger protein or TALE DNA binding domain)

that has been engineered to bind to a target site in a gene of choice and cleavage domain or a cleavage half-domain

[0130] As described in detail above, zinc finger binding domains and TALE DNA binding domains can be engineered to bind to a sequence of choice. *See, for* 5 *example, Beerli et al. (2002) Nature Biotechnol. 20:135-141; Pabo et al. (2001) Ann. Rev. Biochem. 70:313-340; Isalan et al. (2001) Nature Biotechnol. 19:656-660; Segal et al. (2001) Curr. Opin. Biotechnol. 12:632-637; Choo et al. (2000) Curr. Opin. Struct. Biol. 10:411-416.* An engineered zinc finger binding domain or TALE protein can have a novel binding specificity, compared to a naturally-occurring protein.

10 Engineering methods include, but are not limited to, rational design and various types of selection. Rational design includes, for example, using databases comprising triplet (or quadruplet) nucleotide sequences and individual zinc finger or TALE amino acid sequences, in which each triplet or quadruplet nucleotide sequence is associated with one or more amino acid sequences of zinc fingers or TALE repeat units which

15 bind the particular triplet or quadruplet sequence. *See, for example, co-owned U.S. Patents 6,453,242 and 6,534,261.*

[0131] Exemplary selection methods, including phage display and two-hybrid systems, are disclosed in US Patents 5,789,538; 5,925,523; 6,007,988; 6,013,453; 6,410,248; 6,140,466; 6,200,759; and 6,242,568; as well as WO 98/37186; 20 WO 98/53057; WO 00/27878; WO 01/88197 and GB 2,338,237. In addition, enhancement of binding specificity for zinc finger binding domains has been described, for example, in co-owned WO 02/077227.

[0132] Selection of target sites; and methods for design and construction of fusion proteins (and polynucleotides encoding same) are known to those of skill in the 25 art and described in detail in U.S. Patent Application Publication Nos. 20050064474 and 20060188987.

[0133] In addition, as disclosed in these and other references, zinc finger domains, TALEs and/or multi-fingered zinc finger proteins may be linked together using any suitable linker sequences, including for example, linkers of 5 or more 30 amino acids in length. (e.g., TGEKP (SEQ ID NO:131), TGGQRP (SEQ ID NO:132), TGQKP (SEQ ID NO:133), and/or TGSQKP (SEQ ID NO:134)). *See, e.g., U.S. Patent Nos. 6,479,626; 6,903,185; and 7,153,949 for exemplary linker sequences 6 or more amino acids in length.* The proteins described herein may include any

combination of suitable linkers between the individual zinc fingers of the protein.

See, also, PCT Publication No. PCT/US11/00758 published on November 10, 2011.

[0134] Nucleases such as ZFNs, TALENs and/or meganucleases also comprise a nuclease (cleavage domain, cleavage half-domain). As noted above, the 5 cleavage domain may be heterologous to the DNA-binding domain, for example a zinc finger DNA-binding domain and a cleavage domain from a nuclease or a meganuclease DNA-binding domain and cleavage domain from a different nuclease. Heterologous cleavage domains can be obtained from any endonuclease or 10 exonuclease. Exemplary endonucleases from which a cleavage domain can be derived include, but are not limited to, restriction endonucleases and homing endonucleases. See, for example, 2002-2003 Catalogue, New England Biolabs, Beverly, MA; and Belfort *et al.* (1997) *Nucleic Acids Res.* **25**:3379-3388. Additional enzymes which cleave DNA are known (e.g., S1 Nuclease; mung bean nuclease; 15 pancreatic DNase I; micrococcal nuclease; yeast HO endonuclease; *see also* Linn *et al.* (eds.) *Nucleases*, Cold Spring Harbor Laboratory Press, 1993). One or more of these enzymes (or functional fragments thereof) can be used as a source of cleavage domains and cleavage half-domains.

[0135] Similarly, a cleavage half-domain can be derived from any nuclease or portion thereof, as set forth above, that requires dimerization for cleavage activity. In 20 general, two fusion proteins are required for cleavage if the fusion proteins comprise cleavage half-domains. Alternatively, a single protein comprising two cleavage half-domains can be used. The two cleavage half-domains can be derived from the same endonuclease (or functional fragments thereof), or each cleavage half-domain can be derived from a different endonuclease (or functional fragments thereof). In addition, 25 the target sites for the two fusion proteins are preferably disposed, with respect to each other, such that binding of the two fusion proteins to their respective target sites places the cleavage half-domains in a spatial orientation to each other that allows the cleavage half-domains to form a functional cleavage domain, e.g., by dimerizing. Thus, in certain embodiments, the near edges of the target sites are separated by 5-8 30 nucleotides or by 15-18 nucleotides. However any integral number of nucleotides or nucleotide pairs can intervene between two target sites (e.g., from 2 to 50 nucleotide pairs or more). In general, the site of cleavage lies between the target sites.

[0136] Restriction endonucleases (restriction enzymes) are present in many species and are capable of sequence-specific binding to DNA (at a recognition site),

and cleaving DNA at or near the site of binding. Certain restriction enzymes (e.g., Type IIS) cleave DNA at sites removed from the recognition site and have separable binding and cleavage domains. For example, the Type IIS enzyme *Fok* I catalyzes double-stranded cleavage of DNA, at 9 nucleotides from its recognition site on one strand and 13 nucleotides from its recognition site on the other. *See*, for example, US Patents 5,356,802; 5,436,150 and 5,487,994; as well as Li *et al.* (1992) *Proc. Natl. Acad. Sci. USA* **89**:4275-4279; Li *et al.* (1993) *Proc. Natl. Acad. Sci. USA* **90**:2764-2768; Kim *et al.* (1994a) *Proc. Natl. Acad. Sci. USA* **91**:883-887; Kim *et al.* (1994b) *J. Biol. Chem.* **269**:31,978-31,982. Thus, in one embodiment, fusion proteins 5 comprise the cleavage domain (or cleavage half-domain) from at least one Type IIS 10 restriction enzyme and one or more zinc finger binding domains, which may or may not be engineered.

[0137] An exemplary Type IIS restriction enzyme, whose cleavage domain is separable from the binding domain, is *Fok* I. This particular enzyme is active as a 15 dimer. Bitinaite *et al.* (1998) *Proc. Natl. Acad. Sci. USA* **95**: 10,570-10,575. Accordingly, for the purposes of the present disclosure, the portion of the *Fok* I enzyme used in the disclosed fusion proteins is considered a cleavage half-domain. Thus, for targeted double-stranded cleavage and/or targeted replacement of cellular 20 sequences using zinc finger-*Fok* I fusions, two fusion proteins, each comprising a *Fok* I cleavage half-domain, can be used to reconstitute a catalytically active cleavage domain. Alternatively, a single polypeptide molecule containing a zinc finger binding domain and two *Fok* I cleavage half-domains can also be used. Parameters for targeted cleavage and targeted sequence alteration using zinc finger-*Fok* I fusions are 25 provided elsewhere in this disclosure.

[0138] A cleavage domain or cleavage half-domain can be any portion of a protein that retains cleavage activity, or that retains the ability to multimerize (e.g., dimerize) to form a functional cleavage domain.

[0139] Exemplary Type IIS restriction enzymes are described in International Publication WO 07/014275. Additional restriction enzymes also contain separable 30 binding and cleavage domains, and these are contemplated by the present disclosure. *See*, for example, Roberts *et al.* (2003) *Nucleic Acids Res.* **31**:418-420.

[0140] In certain embodiments, the cleavage domain comprises one or more engineered cleavage half-domain (also referred to as dimerization domain mutants)

that minimize or prevent homodimerization, as described, for example, in U.S. Patent Publication Nos. 20050064474, 20060188987 and 20080131962. Amino acid residues at positions 446, 447, 479, 483, 484, 486, 487, 490, 491, 496, 498, 499, 500, 531, 534, 537, and 538 of *Fok* I are all targets for influencing dimerization of the *Fok*

5 I cleavage half-domains.

[0141] Exemplary engineered cleavage half-domains of *Fok* I that form obligate heterodimers include a pair in which a first cleavage half-domain includes mutations at amino acid residues at positions 490 and 538 of *Fok* I and a second cleavage half-domain includes mutations at amino acid residues 486 and 499.

10 **[0142]** Thus, in one embodiment, a mutation at 490 replaces Glu (E) with Lys (K); the mutation at 538 replaces Iso (I) with Lys (K); the mutation at 486 replaced Gln (Q) with Glu (E); and the mutation at position 499 replaces Iso (I) with Lys (K). Specifically, the engineered cleavage half-domains described herein were prepared by mutating positions 490 (E→K) and 538 (I→K) in one cleavage half-domain to 15 produce an engineered cleavage half-domain designated “E490K:I538K” and by mutating positions 486 (Q→E) and 499 (I→L) in another cleavage half-domain to produce an engineered cleavage half-domain designated “Q486E:I499L”. The engineered cleavage half-domains described herein are obligate heterodimer mutants in which aberrant cleavage is minimized or abolished. *See, e.g.*, U.S. Patent 20 Publication No. 2008/0131962. In certain embodiments, the engineered cleavage half-domain comprises mutations at positions 486, 499 and 496 (numbered relative to wild-type *Fok*I), for instance mutations that replace the wild type Gln (Q) residue at position 486 with a Glu (E) residue, the wild type Iso (I) residue at position 499 with a Leu (L) residue and the wild-type Asn (N) residue at position 496 with an Asp (D) or 25 Glu (E) residue (also referred to as a “ELD” and “ELE” domains, respectively). In other embodiments, the engineered cleavage half-domain comprises mutations at positions 490, 538 and 537 (numbered relative to wild-type *Fok*I), for instance mutations that replace the wild type Glu (E) residue at position 490 with a Lys (K) residue, the wild type Iso (I) residue at position 538 with a Lys (K) residue, and the 30 wild-type His (H) residue at position 537 with a Lys (K) residue or a Arg (R) residue (also referred to as “KKK” and “KKR” domains, respectively). In other embodiments, the engineered cleavage half-domain comprises mutations at positions

490 and 537 (numbered relative to wild-type FokI), for instance mutations that
replace the wild type Glu (E) residue at position 490 with a Lys (K) residue and the
wild-type His (H) residue at position 537 with a Lys (K) residue or a Arg (R) residue
(also referred to as “KIK” and “KIR” domains, respectively). (See US application
5 12/931,660).

[0143] Engineered cleavage half-domains described herein can be prepared
using any suitable method, for example, by site-directed mutagenesis of wild-type
cleavage half-domains (*Fok I*) as described in U.S. Patent Publication Nos.
20050064474 and 20080131962.

10 [0144] Alternatively, nucleases may be assembled *in vivo* at the nucleic acid
target site using so-called “split-enzyme” technology (*see e.g.* U.S. Patent Publication
No. 20090068164). Components of such split enzymes may be expressed either on
separate expression constructs, or can be linked in one open reading frame where the
individual components are separated, for example, by a self-cleaving 2A peptide or
15 IRES sequence. Components may be individual zinc finger binding domains or
domains of a meganuclease nucleic acid binding domain.

[0145] Nucleases (*e.g.*, ZFNs and/or TALENs) can be screened for activity
prior to use, for example in a yeast-based chromosomal system as described in WO
2009/042163 and 20090068164. Nuclease expression constructs can be readily
20 designed using methods known in the art. *See, e.g.*, United States Patent Publications
20030232410; 20050208489; 20050026157; 20050064474; 20060188987;
20060063231; and International Publication WO 07/014275. Expression of the
nuclease may be under the control of a constitutive promoter or an inducible
25 promoter, for example the galactokinase promoter which is activated (de-repressed) in
the presence of raffinose and/or galactose and repressed in presence of glucose.

Delivery

[0146] The proteins (*e.g.*, ZFPs, TALEs, ZFNs and/or TALENs),
polynucleotides encoding same and compositions comprising the proteins and/or
30 polynucleotides described herein may be delivered to a target cell by any suitable
means, including, for example, by injection of the protein or mRNA. Suitable cells
include but not limited to eukaryotic and prokaryotic cells and/or cell lines. Non-
limiting examples of such cells or cell lines generated from such cells include T-cells,
COS, CHO (*e.g.*, CHO-S, CHO-K1, CHO-DG44, CHO-DUXB11, CHO-DUKX,

CHOK1SV), VERO, MDCK, WI38, V79, B14AF28-G3, BHK, HaK, NS0, SP2/0-Ag14, HeLa, HEK293 (*e.g.*, HEK293-F, HEK293-H, HEK293-T), and perC6 cells as well as insect cells such as *Spodoptera frugiperda* (Sf), or fungal cells such as *Saccharomyces*, *Pichia* and *Schizosaccharomyces*. In certain embodiments, the cell line is a CHO-K1, MDCK or HEK293 cell line. Suitable cells also include stem cells such as, by way of example, embryonic stem cells, induced pluripotent stem cells (iPS cells), hematopoietic stem cells, neuronal stem cells and mesenchymal stem cells.

5 [0147] Methods of delivering proteins comprising DNA-binding domains as described herein are described, for example, in U.S. Patent Nos. 6,453,242; 10 6,503,717; 6,534,261; 6,599,692; 6,607,882; 6,689,558; 6,824,978; 6,933,113; 6,979,539; 7,013,219; and 7,163,824.

15 [0148] DNA binding domains and fusion proteins comprising these DNA binding domains as described herein may also be delivered using vectors containing sequences encoding one or more of the DNA-binding protein(s). Additionally, donor 20 nucleic acids also may be delivered via these vectors. Any vector systems may be used including, but not limited to, plasmid vectors, retroviral vectors, lentiviral vectors, adenovirus vectors, poxvirus vectors; herpesvirus vectors and adeno-associated virus vectors, etc. *See, also*, U.S. Patent Nos. 6,534,261; 6,607,882; 6,824,978; 6,933,113; 6,979,539; 7,013,219; and 7,163,824. Furthermore, it will be apparent that any of these vectors may comprise one or more DNA-binding protein-encoding sequences and/or donor nucleic acids as appropriate. Thus, when one or more DNA-binding proteins as described herein are introduced into the cell, and donor DNAs as appropriate, they may be carried on the same vector or on different vectors. When multiple vectors are used, each vector may comprise a sequence 25 encoding one or multiple DNA-binding proteins and donor nucleic acids as desired.

30 [0149] Conventional viral and non-viral based gene transfer methods can be used to introduce nucleic acids encoding engineered DNA-binding proteins in cells (*e.g.*, mammalian cells) and target tissues and to co-introduce donors as desired. Such methods can also be used to administer nucleic acids encoding DNA-binding proteins to cells *in vitro*. In certain embodiments, nucleic acids encoding DNA-binding proteins are administered for *in vivo* or *ex vivo* gene therapy uses. Non-viral vector delivery systems include DNA plasmids, naked nucleic acid, and nucleic acid

complexed with a delivery vehicle such as a liposome or poloxamer. Viral vector delivery systems include DNA and RNA viruses, which have either episomal or integrated genomes after delivery to the cell. For a review of gene therapy procedures, see Anderson, *Science* 256:808-813 (1992); Nabel & Felgner, *TIBTECH*

5 11:211-217 (1993); Mitani & Caskey, *TIBTECH* 11:162-166 (1993); Dillon, *TIBTECH* 11:167-175 (1993); Miller, *Nature* 357:455-460 (1992); Van Brunt, *Biotechnology* 6(10):1149-1154 (1988); Vigne, *Restorative Neurology and Neuroscience* 8:35-36 (1995); Kremer & Perricaudet, *British Medical Bulletin* 51(1):31-44 (1995); Haddada *et al.*, in *Current Topics in Microbiology and*

10 *Immunology* Doerfler and Böhm (eds.) (1995); and Yu *et al.*, *Gene Therapy* 1:13-26 (1994).

[0150] Methods of non-viral delivery of nucleic acids include electroporation, lipofection, microinjection, biolistics, virosomes, liposomes, immunoliposomes, polycation or lipid:nucleic acid conjugates, naked DNA, artificial virions, and agent-enhanced uptake of DNA. Sonoporation using, *e.g.*, the Sonitron 2000 system (Rich-Mar) can also be used for delivery of nucleic acids.

[0151] Additional exemplary nucleic acid delivery systems include those provided by Amaxa Biosystems (Cologne, Germany), Maxcyte, Inc. (Rockville, Maryland), BTX Molecular Delivery Systems (Holliston, MA) and Copernicus

20 Therapeutics Inc, (*see* for example US6008336). Lipofection is described in *e.g.*, US 5,049,386, US 4,946,787; and US 4,897,355) and lipofection reagents are sold commercially (*e.g.*, Transfectam™ and Lipofectin™). Cationic and neutral lipids that are suitable for efficient receptor-recognition lipofection of polynucleotides include those of Felgner, WO 91/17424, WO 91/16024. Delivery can be to cells (*ex vivo* administration) or target tissues (*in vivo* administration).

[0152] The preparation of lipid:nucleic acid complexes, including targeted liposomes such as immunolipid complexes, is well known to one of skill in the art (*see, e.g.*, Crystal, *Science* 270:404-410 (1995); Blaese *et al.*, *Cancer Gene Ther.* 2:291-297 (1995); Behr *et al.*, *Bioconjugate Chem.* 5:382-389 (1994); Remy *et al.*,

30 *Bioconjugate Chem.* 5:647-654 (1994); Gao *et al.*, *Gene Therapy* 2:710-722 (1995); Ahmad *et al.*, *Cancer Res.* 52:4817-4820 (1992); U.S. Pat. Nos. 4,186,183, 4,217,344, 4,235,871, 4,261,975, 4,485,054, 4,501,728, 4,774,085, 4,837,028, and 4,946,787).

[0153] Additional methods of delivery include the use of packaging the nucleic acids to be delivered into EnGeneIC delivery vehicles (EDVs). These EDVs

are specifically delivered to target tissues using bispecific antibodies where one arm of the antibody has specificity for the target tissue and the other has specificity for the EDV. The antibody brings the EDVs to the target cell surface and then the EDV is brought into the cell by endocytosis. Once in the cell, the contents are released (see

5 MacDiarmid *et al* (2009) *Nature Biotechnology* vol 27(7) p. 643).

[0154] The use of RNA or DNA viral based systems for the delivery of nucleic acids encoding engineered DNA-binding proteins and donors as desired takes advantage of highly evolved processes for targeting a virus to specific cells in the body and trafficking the viral payload to the nucleus. Viral vectors can be

10 administered directly to patients (*in vivo*) or they can be used to treat cells *in vitro* and the modified cells are administered to patients (*ex vivo*). Conventional viral based systems for the delivery of DNA-binding proteins and donors include, but are not limited to, retroviral, lentivirus, adenoviral, adeno-associated, vaccinia and herpes simplex virus vectors for gene transfer. Integration in the host genome is possible

15 with the retrovirus, lentivirus, and adeno-associated virus gene transfer methods, often resulting in long term expression of the inserted transgene. Additionally, high transduction efficiencies have been observed in many different cell types and target tissues.

[0155] The tropism of a retrovirus can be altered by incorporating foreign envelope proteins, expanding the potential target population of target cells. Lentiviral vectors are retroviral vectors that are able to transduce or infect non-dividing cells and typically produce high viral titers. Selection of a retroviral gene transfer system depends on the target tissue. Retroviral vectors are comprised of *cis*-acting long terminal repeats with packaging capacity for up to 6-10 kb of foreign sequence. The 25 minimum *cis*-acting LTRs are sufficient for replication and packaging of the vectors, which are then used to integrate the therapeutic gene into the target cell to provide permanent transgene expression. Widely used retroviral vectors include those based upon murine leukemia virus (MuLV), gibbon ape leukemia virus (GaLV), Simian Immunodeficiency virus (SIV), human immunodeficiency virus (HIV), and combinations thereof (see, e.g., Buchscher *et al.*, *J. Virol.* 66:2731-2739 (1992); Johann *et al.*, *J. Virol.* 66:1635-1640 (1992); Sommerfelt *et al.*, *Virol.* 176:58-59 (1990); Wilson *et al.*, *J. Virol.* 63:2374-2378 (1989); Miller *et al.*, *J. Virol.* 65:2220-2224 (1991); PCT/US94/05700).

[0156] In applications in which transient expression is preferred, adenoviral based systems can be used. Adenoviral based vectors are capable of very high transduction efficiency in many cell types and do not require cell division. With such vectors, high titer and high levels of expression have been obtained. This vector can 5 be produced in large quantities in a relatively simple system. Adeno-associated virus (“AAV”) vectors are also used to transduce cells with target nucleic acids, *e.g.*, in the *in vitro* production of nucleic acids and peptides, and for *in vivo* and *ex vivo* gene therapy procedures (*see, e.g.*, West *et al.*, *Virology* 160:38-47 (1987); U.S. Patent No. 4,797,368; WO 93/24641; Kotin, *Human Gene Therapy* 5:793-801 (1994);

10 Muzyczka, *J. Clin. Invest.* 94:1351 (1994). Construction of recombinant AAV vectors are described in a number of publications, including U.S. Pat. No. 5,173,414; Tratschin *et al.*, *Mol. Cell. Biol.* 5:3251-3260 (1985); Tratschin, *et al.*, *Mol. Cell. Biol.* 4:2072-2081 (1984); Hermonat & Muzyczka, *PNAS* 81:6466-6470 (1984); and Samulski *et al.*, *J. Virol.* 63:03822-3828 (1989).

15 [0157] At least six viral vector approaches are currently available for gene transfer in clinical trials, which utilize approaches that involve complementation of defective vectors by genes inserted into helper cell lines to generate the transducing agent.

[0158] pLASN and MFG-S are examples of retroviral vectors that have been 20 used in clinical trials (Dunbar *et al.*, *Blood* 85:3048-305 (1995); Kohn *et al.*, *Nat. Med.* 1:1017-102 (1995); Malech *et al.*, *PNAS* 94:22 12133-12138 (1997)). PA317/pLASN was the first therapeutic vector used in a gene therapy trial. (Blaese *et al.*, *Science* 270:475-480 (1995)). Transduction efficiencies of 50% or greater have been observed for MFG-S packaged vectors. (Ellem *et al.*, *Immunol Immunother.* 25 44(1):10-20 (1997); Dranoff *et al.*, *Hum. Gene Ther.* 1:111-2 (1997)).

[0159] Recombinant adeno-associated virus vectors (rAAV) are a promising alternative gene delivery systems based on the defective and nonpathogenic parvovirus adeno-associated type 2 virus. All vectors are derived from a plasmid that 30 retains only the AAV 145 bp inverted terminal repeats flanking the transgene expression cassette. Efficient gene transfer and stable transgene delivery due to integration into the genomes of the transduced cell are key features for this vector system. (Wagner *et al.*, *Lancet* 351:9117 1702-3 (1998), Kearns *et al.*, *Gene Ther.* 9:748-55 (1996)). Other AAV serotypes, including AAV1, AAV3, AAV4, AAV5,

AAV6, AAV8, AAV9 and AAV10 can also be used in accordance with the present invention.

[0160] Replication-deficient recombinant adenoviral vectors (Ad) can be produced at high titer and readily infect a number of different cell types. Most 5 adenovirus vectors are engineered such that a transgene replaces the Ad E1a, E1b, and/or E3 genes; subsequently the replication defective vector is propagated in human 293 cells that supply deleted gene function in *trans*. Ad vectors can transduce multiple types of tissues *in vivo*, including nondividing, differentiated cells such as those found in liver, kidney and muscle. Conventional Ad vectors have a large 10 carrying capacity. An example of the use of an Ad vector in a clinical trial involved polynucleotide therapy for antitumor immunization with intramuscular injection (Sterman *et al.*, *Hum. Gene Ther.* 7:1083-9 (1998)). Additional examples of the use of adenovirus vectors for gene transfer in clinical trials include Rosenecker *et al.*, *Infection* 24:1 5-10 (1996); Sterman *et al.*, *Hum. Gene Ther.* 9:7 1083-1089 (1998); 15 Welsh *et al.*, *Hum. Gene Ther.* 2:205-18 (1995); Alvarez *et al.*, *Hum. Gene Ther.* 5:597-613 (1997); Topf *et al.*, *Gene Ther.* 5:507-513 (1998); Sterman *et al.*, *Hum. Gene Ther.* 7:1083-1089 (1998).

[0161] Packaging cells are used to form virus particles that are capable of infecting a host cell. Such cells include 293 cells, which package adenovirus, and ψ2 20 cells or PA317 cells, which package retrovirus. Viral vectors used in gene therapy are usually generated by a producer cell line that packages a nucleic acid vector into a viral particle. The vectors typically contain the minimal viral sequences required for packaging and subsequent integration into a host (if applicable), other viral sequences being replaced by an expression cassette encoding the protein to be expressed. The 25 missing viral functions are supplied in *trans* by the packaging cell line. For example, AAV vectors used in gene therapy typically only possess inverted terminal repeat (ITR) sequences from the AAV genome which are required for packaging and integration into the host genome. Viral DNA is packaged in a cell line, which contains a helper plasmid encoding the other AAV genes, namely *rep* and *cap*, but 30 lacking ITR sequences. The cell line is also infected with adenovirus as a helper. The helper virus promotes replication of the AAV vector and expression of AAV genes from the helper plasmid. The helper plasmid is not packaged in significant amounts due to a lack of ITR sequences. Contamination with adenovirus can be reduced by, *e.g.*, heat treatment to which adenovirus is more sensitive than AAV.

[0162] In many gene therapy applications, it is desirable that the gene therapy vector be delivered with a high degree of specificity to a particular tissue type. Accordingly, a viral vector can be modified to have specificity for a given cell type by expressing a ligand as a fusion protein with a viral coat protein on the outer surface of the virus. The ligand is chosen to have affinity for a receptor known to be present on the cell type of interest. For example, Han *et al.*, *Proc. Natl. Acad. Sci. USA* 92:9747-9751 (1995), reported that Moloney murine leukemia virus can be modified to express human heregulin fused to gp70, and the recombinant virus infects certain human breast cancer cells expressing human epidermal growth factor receptor. This principle 5 can be extended to other virus-target cell pairs, in which the target cell expresses a receptor and the virus expresses a fusion protein comprising a ligand for the cell-surface receptor. For example, filamentous phage can be engineered to display antibody fragments (*e.g.*, FAB or Fv) having specific binding affinity for virtually any chosen cellular receptor. Although the above description applies primarily to viral 10 vectors, the same principles can be applied to nonviral vectors. Such vectors can be engineered to contain specific uptake sequences which favor uptake by specific target 15 cells.

[0163] Gene therapy vectors can be delivered *in vivo* by administration to an individual patient, typically by systemic administration (*e.g.*, intravenous, 20 intraperitoneal, intramuscular, subdermal, or intracranial infusion) or topical application, as described below. Alternatively, vectors can be delivered to cells *ex vivo*, such as cells explanted from an individual patient (*e.g.*, lymphocytes, bone marrow aspirates, tissue biopsy) or universal donor hematopoietic stem cells, followed by re-implantation of the cells into a patient, usually after selection for cells 25 which have incorporated the vector.

[0164] *Ex vivo* cell transfection for diagnostics, research, transplant or for gene therapy (*e.g.*, via re-infusion of the transfected cells into the host organism) is well known to those of skill in the art. In a preferred embodiment, cells are isolated from the subject organism, transfected with a DNA-binding protein nucleic acid (gene or cDNA), and re-infused back into the subject organism (*e.g.*, patient).

30 Various cell types suitable for *ex vivo* transfection are well known to those of skill in the art (*see, e.g.*, Freshney *et al.*, *Culture of Animal Cells, A Manual of Basic Technique* (3rd ed. 1994)) and the references cited therein for a discussion of how to isolate and culture cells from patients).

[0165] In one embodiment, stem cells are used in *ex vivo* procedures for cell transfection and gene therapy. The advantage to using stem cells is that they can be differentiated into other cell types *in vitro*, or can be introduced into a mammal (such as the donor of the cells) where they will engraft in the bone marrow. Methods for 5 differentiating CD34+ cells *in vitro* into clinically important immune cell types using cytokines such as GM-CSF, IFN- γ and TNF- α are known (see Inaba *et al.*, *J. Exp. Med.* 176:1693-1702 (1992)).

[0166] Stem cells are isolated for transduction and differentiation using known methods. For example, stem cells are isolated from bone marrow cells by 10 panning the bone marrow cells with antibodies which bind unwanted cells, such as CD4+ and CD8+ (T cells), CD45+ (panB cells), GR-1 (granulocytes), and Iad (differentiated antigen presenting cells) (see Inaba *et al.*, *J. Exp. Med.* 176:1693-1702 (1992)).

[0167] Stem cells that have been modified may also be used in some 15 embodiments. For example, neuronal stem cells that have been made resistant to apoptosis may be used as therapeutic compositions where the stem cells also contain the ZFP TFs of the invention. Resistance to apoptosis may come about, for example, by knocking out BAX and/or BAK using BAX- or BAK-specific ZFNs (see, US patent application no. 12/456,043) in the stem cells, or those that are disrupted in a 20 caspase, again using caspase-6 specific ZFNs for example. These cells can be transfected with the ZFP TFs that are known to regulate HLA.

[0168] Vectors (e.g., retroviruses, adenoviruses, liposomes, etc.) containing therapeutic DNA-binding proteins (or nucleic acids encoding these proteins) can also be administered directly to an organism for transduction of cells *in vivo*. 25 Alternatively, naked DNA can be administered. Administration is by any of the routes normally used for introducing a molecule into ultimate contact with blood or tissue cells including, but not limited to, injection, infusion, topical application and electroporation. Suitable methods of administering such nucleic acids are available and well known to those of skill in the art, and, although more than one route can be 30 used to administer a particular composition, a particular route can often provide a more immediate and more effective reaction than another route.

[0169] Methods for introduction of DNA into hematopoietic stem cells are disclosed, for example, in U.S. Patent No. 5,928,638. Vectors useful for introduction

of transgenes into hematopoietic stem cells, *e.g.*, CD34⁺ cells, include adenovirus Type 35.

[0170] Vectors suitable for introduction of transgenes into immune cells (*e.g.*, T-cells) include non-integrating lentivirus vectors. *See, for example, Ory et al. (1996)*

5 *Proc. Natl. Acad. Sci. USA* **93**:11382-11388; Dull *et al.* (1998) *J. Virol.* **72**:8463-8471; Zuffery *et al.* (1998) *J. Virol.* **72**:9873-9880; Follenzi *et al.* (2000) *Nature Genetics* **25**:217-222.

10 [0171] Pharmaceutically acceptable carriers are determined in part by the particular composition being administered, as well as by the particular method used to administer the composition. Accordingly, there is a wide variety of suitable formulations of pharmaceutical compositions available, as described below (*see, e.g., Remington's Pharmaceutical Sciences*, 17th ed., 1989).

15 [0172] As noted above, the disclosed methods and compositions can be used in any type of cell including, but not limited to, prokaryotic cells, fungal cells, Archaeal cells, plant cells, insect cells, animal cells, vertebrate cells, mammalian cells and human cells, including T-cells and stem cells of any type. Suitable cell lines for protein expression are known to those of skill in the art and include, but are not limited to COS, CHO (*e.g.*, CHO-S, CHO-K1, CHO-DG44, CHO-DUXB11), VERO, MDCK, WI38, V79, B14AF28-G3, BHK, HaK, NS0, SP2/0-Ag14, HeLa, HEK293 (e.g., HEK293-F, HEK293-H, HEK293-T), perC6, insect cells such as *Spodoptera frugiperda* (Sf), and fungal cells such as *Saccharomyces*, *Pichia* and *Schizosaccharomyces*. Progeny, variants and derivatives of these cell lines can also be used.

25 Applications

[0173] The disclosed compositions and methods can be used for any application in which it is desired to modulate HLA genes and/or HLA regulators. In particular, these methods and compositions can be used where modulation or modification of a HLA allele is desired, including but not limited to, therapeutic and research applications.

[0174] Diseases and conditions which are tied to HLA include Addison's disease, ankylosing spondylitis, Behçet's disease, Buerger's disease, celiac disease, chronic active hepatitis, Graves' disease, juvenile rheumatoid arthritis, psoriasis, psoriatic arthritis, rheumatoid arthritis, Sjögren syndrome, and lupus erythematosus,

among others. In addition, modification of a HLA gene may be useful in conjunction with other genetic modifications of a cell of interest. For example, modification of a target cell such as a CTL with a chimeric antigen receptor to change the CTL's specificity may be combined with HLA modification *ex vivo* in order to develop a cell therapeutic that may be used in most any patient in need thereof.

5 [0175] In addition, the materials and methods of the invention can be used in the treatment, prevention or amelioration of graft-versus-host-disease. Graft-versus-host disease (GVHD) is a common complication when allogenic T-cells (*e.g.*, bone marrow and/or blood transfusion) are administered to a patient. The functional 10 immune cells in the infused material recognize the recipient as "foreign" and mount an immunologic attack. By modulating HLA and/or TCR expression in allogenic T cells, "off the shelf" T cells (*e.g.*, CD19-specific T-cells) can be administered on demand as "drugs" because the risk of GVHD is reduced or eliminated.

15 [0176] Methods and compositions also include stem cell compositions wherein a copy of a HLA allele within the stem cells has been modified using a HLA-specific or HLA regulator specific ZFN. For example, HLA modified hematopoietic stem cells can be introduced into a patient following bone marrow ablation. These altered HSC would allow the re-colonization of the patient without loss of the graft due to rejection. The introduced cells may also have other alterations 20 to help during subsequent therapy (*e.g.*, chemotherapy resistance) to treat the underlying disease.

25 [0177] The methods and compositions of the invention are also useful for the development of HLA modified platelets, for example for use as therapeutics. Thus, HLA modified platelets may be used to treat thrombocytopenic disorders such as idiopathic thrombocytopenic purpura, thrombotic thrombocytopenic purpura and drug-induced thrombocytopenic purpura (*e.g.* heparin-induced thrombocytopenia). Other platelet disorders that may be treated with the HLA modified platelets of the invention include Gaucher's disease, aplastic anemia, Onyalai, fetomaternal 30 alloimmune thrombocytopenia, HELLP syndrome, cancer and side effects from some chemotherapeutic agents. The HLA modified platelets also have use in as an "off the shelf" therapy in emergency room situations with trauma patients.

[0178] The methods and compositions of the invention can be used in xenotransplantation. Specifically, by way of example only, pig organs can be used for transplantation into humans wherein the porcine MHC genes have been deleted and/or

replaced with human HLA genes. Strains of pigs can be developed (from pig embryos that have had HLA targeting ZFNs encoded by mRNAs injected into them such that the endogenous MHC genes are disrupted, or from somatic cell nuclear transfer into pig embryos using nuclei of cells that have been successfully had their HLA genes targeted) that contain these useful genetic mutations, and these animals may be grown for eventual organ harvest. This will prevent rejection of these organs in humans and increase the chances for successful transplantation.

5 [0179] The methods and compositions of the invention are also useful for the design and implementation of *in vitro* and *in vivo* models, for example, animal models 10 of HLA or other disorders, which allows for the study of these disorders.

EXAMPLES

Example 1: Design, Construction and general characterization of zinc finger protein nucleases (ZFN)

15 [0180] Zinc finger proteins were designed and incorporated into plasmids or adenoviral vectors essentially as described in Urnov *et al.* (2005) *Nature* 435(7042):646-651, Perez *et al* (2008) *Nature Biotechnology* 26(7):808-816, and as described in U.S. Patent No. 6,534,261. In addition, see United States provisional patent application 61/280,863 for ZFNs targeted to TRAC and TRBC. Table 1 shows 20 the recognition helices within the DNA binding domain of exemplary ZFPs while Table 2 shows the target sites for these ZFPs. Nucleotides in the target site that are contacted by the ZFP recognition helices are indicated in uppercase letters; non-contacted nucleotides indicated in lowercase.

25 **Example 2: ZFNs specific for HLA class I genes**

[0181] The HLA complexes often contain several family members co-localized within the same general area of the genome. Figure 1 presents a schematic of the arrangement of the major genes in the HLA class I and class I loci found on chromosome 6.

30

ZFNs directed against the HLA A locus

[0182] ZFN pairs were made to target the HLA A locus, with some made specifically against the A2 allele while others were made to target the A3 locus or both. For the A2 and A3 alleles, two pairs were tested such that ZFN 18889 was

paired with 18881, and 18889 was also paired with 24859. When the successful pairing of the ZFNs creates a DSB at the desired location, the site is often repaired using non-homologous end joining (NHEJ). This process frequently results in the insertion or deletion of a small number of nucleotides at the site of the mended junction, and so when the DNA around the junction is amplified by PCR, and then subjected to a Cel-I mismatch assay as described, for example, in U.S. Patent Publication Nos. 20080015164; 20080131962 and 20080159996, (Surveyor™, Transgenomic), using the products amplified with respective primers, the frequency of these insertions or deletions (collectively “indels”) can be calculated when the products of the assay are subjected to gel electrophoresis. Thus, the A2/A3 specific pairs were examined for activity against their targets using the Cel-I assay. Cells as indicated were transfected with GFP control or each of the pairs of ZFNs. DNA was prepared from the cells one day post transfection, and the results are shown in Figure 2. Arrows indicate cleavage was found only in samples containing ZFN pairs, but was not found in the control samples wherein cells were transfected with ZFNs specific for GFP. The percent gene modification is shown at the bottom of each lane.

[0183] The 18889/18881 pair gave approximately 3% gene modification while the 18889/24859 pair gave approximately 6% NHEJ against the HLA A2 gene when plasmids encoding the ZFNs were transfected into HEK293 cells. For the A3 allele, the 18889/18881 pair gave 9% and the 18889/24859 pair gave 10% NHEJ activity. Since these pairs are capable of cutting both the A2 and A3 alleles, it is possible to create a A2/A3 double knock-out cell line.

[0184] The presence of the HLA A marker on the cell surface was analyzed by standard FACS analysis. Briefly, A2, A3 or A2,A3 disrupted HEK293 cells were stained. HLA-A2 staining was done by anti-HLA-A2 PE (BD BioSciences, clone BB7.2). Mouse IgG2bk PE (BD BioSciences) was used for isotype control. For HLA-A3, we first stained these cells with biotinylated anti-HLA-A3 Ab (Abcam, clone 4i53) and then SA-PE (BD). The negative controls in each experiment were: HLA-A2- IgG2bk PE, HLA-A3- SA-PE staining without HLA-A3 Ab.

[0185] In these experiments, a positive control was performed using the isotype control antibody described above where the results are seen in the figures as a black line that is constant in all samples. The cultures were then either stimulated for HLA expression by addition of IFN gamma (600 IU/mL) + TNF (10 mg/mL) for 48 hours, or used without stimulation.

[0186] As shown in Figure 3, the lines closest to the isotype control peak are the samples lacking stimulation, while the shifted peaks are those in the presence of the IFN γ and TNF (see Figure legend). The set of figures on the left hand column are all probed with the anti-HLA A2 antibody, while those on the right hand column were probed with the anti-HLA A3 antibody. As shown, the HLA markers as indicated are no longer detectable when the corresponding HLA genes have been functionally disrupted.

[0187] Next, the HLA A knock out HEK293 cell lines were analyzed to see if they could be lysed by HLA-A restricted CTL cell lines. The methodology for these experiments was as follows. Target cells were labeled with 0.1 mCi of ^{51}Cr for 2 hours. After washing with ice-cold RPMI1640 supplemented with 10% FBS thrice, labeled cells were diluted and distributed at 1×10^3 target cells / 100 μL per well in 96-well, v-bottomed plates. After 30 minutes incubation at room temperature with 10-fold serial dilutions of the peptides, CTL were added at indicated effector target ratio. After 4hr incubation at 37°C, 5%CO₂ incubator, 50 μl of supernatants were collected and count on TopCount (Perkin Elmer). All assays were performed in triplicate. Parental HEK293 cell lines and HLA knocked down HEK293 clones were treated with 600 IU/mL of interferon- γ (IFN- γ ; R&D systems®) and 10 ng/mL of tissue necrosis factor- α (TNF- α ; R&D systems®) for 48 hours before assay. The percent specific lysis was calculated as follows: $((\text{experimental cpm} - \text{spontaneous cpm}) / (\text{maximum cpm} - \text{spontaneous cpm})) \times 100$. In these examples, the peptide antigen target was added in for display by any functioning HLA class I complexes, and in the presence of a functioning HLA A-peptide complex, the CTL clones are able to attack the cells and cause lysis.

[0188] As shown in Figure 4, the HEK293 clones lacking the A2 or the A3 HLA makers were resistant to lysis induced by either the 7A7 PANE1/A3 CTL clone (panel A) or the GAS2B3-5 C19ORF48/A2 CTL clone (panel B) in the presence of their cognate peptide antigens.

[0189] ZFN mediated HLA k.o. was repeated in primary T cells. mRNAs encoding the 18889 (containing the KKR *FokI* variation) and 24859 (containing the ELD *FokI* variation) ZFNs were nucleofected into primary T cells of a homozygous HLA A2 genotype as follows. 5×10^6 primary T cells (isolated by standard methods) were nucleofected using an Amaxa Nucleofector® system (program T20) with the ZFN encoding mRNAs using 2.5 – 10 μg each mRNA per reaction in 100 μL of

buffer as supplied by the manufacturer (Lonza). These cells were then analyzed by FACS analysis to determine if the HLA A2 markers were present on the cell surface by standard methodology.

[0190] As shown in Figure 5, the percent of cells lacking HLA-A expression 5 ranged from approximately 19- 42% following this treatment. Figure 5A shows the percent of cells lacking HLA-A2 under standard treatment conditions, while Figure 5B shows the percent of cells lacking HLA-A2 using the “transient cold shock” treatment conditions (see co-owned US patent application number 12/800,599).

[0191] In addition, we verified that the loss of HLA A2 expression was caused 10 by ZFN mediated modification of the HLA A2 gene by Cel I analysis as described previously. Figure 6 shows the Cel I data where the determined percent NHEJ activity at the ZFN target site ranged from 3-28%. In this figure, “wt” refers to a wild type *FokI* domain, while “mut” refers to the EL/KK *FokI* mutant pair described above. These data demonstrate that the methods and compositions of the invention 15 can be used to delete HLA A expression and create HLA A null cell lines and primary T cells.

[0192] HLA A knock out cells can be enriched to increase the percent HLA A null cells present. A ZFN treated population of T cells, where some low percent of 20 the cells were HLA A null were treated with anti-HLA A2 antibodies tagged with phycoerythrin (PE) (BD BioSciences clone 7.2). Next, beads tagged with an anti-PE antibodies (Miltenyi) were used to bind and thus separate the cells expressing HLA A2 from the HLA A2 null cells according to the manufacturer’s directions. Using this technique, the cell populations went from a range of 5.1-34% HLA A null cells as assayed by FACS analysis to a range of 92-95% HLA A2 null.

25

ZFNs directed to the HLA B and C loci

[0193] ZFNs were constructed to target the HLA B and C loci and tested using the Cel I assay as described above.

[0194] As shown in Figure 7, these ZFN were successfully able to induce 30 gene modification within both of these genes (HLA C knock out is shown in panel A using ZFNs 25588/25589 while the HLA B knock out in panel B was made using the ZFN pair 25316/25317). These targets are located within the gene sequences, so can be used to create HLA B and HLA C knock out clones.

Large deletions of MHC Class I complex

[0195] ZFNs were also designed to allow for a large deletion with the HLA class I locus which simultaneously deletes the HLA B and HLA C genes. These sets of ZFNs were designed to cut upstream of the HLA B gene (HLA B-up) and

5 downstream of the HLA C gene (HLA C-down). These ZFN pairs were tested individually using the Cel I assay as described above to see the degree of cutting as assayed by NHEJ activity.

[0196] Figure 8A shows the HLA C-down results for pair 15296/15298 for both wt *FokI* domains (wt) and the EL/KK *FokI* domain (mut). Figure 8B shows a 10 similar set of data for the HLA B-up pairs 15267/15265 and 17454/17456 in K562 cells. Percent gene modification is indicated at the bottom of the lanes ("% NHEJ"). These ZFNs were then used to test if the HLA B and HLA C genes could be deleted by a combination of these two sets of ZFNs. Figure 9 shows a diagram of the assay used (panel A), and also shows the results of the PCR (panel B). K562 cells were 15 transfected with the two sets of ZFNs and DNA isolated from the cells 3 or 10 days after transfection as indicated.

[0197] PCR was performed using primers flanking the region between the HLA-B and HLA-C as illustrated in Figure 9A. Because of the large amount of DNA to be deleted by a successful double deletion (approximately 100Kb), the PCR 20 reaction is only successful when the deletion has been made. Figure 9B shows a gel with a PCR reaction following treatment with the two ZFN pairs. The left side of the gel shows a dilution series of a plasmid used for rough quantitation of the amount of deletion PCR product present on the right side of the gel. In this figure, "wt" refers to a wild type *FokI* domain, while "mut" refers to the EL/KK *FokI* mutant pair. The 25 results show that approximately 5% of the DNA present contained the deletion.

[0198] Clones derived from this experiment were subjected to FACs analysis to observe the expression of the class I complex overall, and specifically the HLA B and C genes in particular. This was done as described above using an anti-class I antibody to analyze class I expression, and an anti-HLA BC antibody to analyze HLA 30 BC. The results showed that in the parental K562 cell line, 9.02% of the cells expressed the class I complex in general, and 15.98% of the cells expressed HLA B and C. In one knock out line, the class I expression level was 3.88% and HLA BC expression was 7.82%. It is likely that this line does not contain a knock out on both

HLA BC alleles, and so it is not unexpected that the expression would be only reduced rather than eliminated.

Example 3: ZFNs specific for HLA class I regulator genes

5 [0199] In addition to examining the action of ZFNs specific for class I HLA genes, we also looked at the effects of ZFNs directed to potential class I regulators, namely TAP1, TAP2 and tapasin. ZFNs were made against these gene targets, and their design details are shown in Tables 1 and 2.

10 [0200] The ZFNs were transfected into HEK293 cells and tested for gene modification activity by the Cel-I assay as described above

[0201] As shown in Figures 10 and 11, ZFN pairs modified their targets. Figure 10 A shows the results of the ZFNs specific for TAP1 (pair 28386/28385) where the data indicates an approximate 39% gene modification activity. Figure 10B shows that the ZFN pair 28394/28393 modifies Tap2 with about 49% efficiency.

15 15 Figure 11 shows similar results for ZFNs specific for the Tapasin gene (pair 28406/28405 and pair 28404/28403), where the data indicates an approximate 34 and 64% gene modification activity, respectively.

Example 4: ZFNs specific for HLA class II genes

20 [0202] As described above in Example 2 for the class I genes, large deletions were also made in the class II gene cluster. Two ZFN pairs were identified that cleave the target DNA upstream of the DBP2 gene (15872 and 15873) and downstream of the DRA gene (15909 and 15910), respectively. Each pair was analyzed by Cel I analysis in K562 cells as described above. The Cel I analysis

25 displayed in Figure 12 shows that for the 15872/15873 pair, 13% NHEJ was found using the ZFN versions containing the wild type (wt) *FokI* domains, while when the pair was made with the EL/KK *FokI* pair (mut) as described previously, the NHEJ activity was found to be approximately 28%. For the 15909/15910 pair, 6 and 11% NHEJ activity was found using the ZFN versions containing the wild type (wt) *FokI* domains, while 14% NHEJ activity was observed with the EL/KK *FokI* domain pair (mut).

30 [0203] The two ZFN pairs were used together to delete the section of DNA between DBP2 and DRA and then a PCR with primers flanking the deletion was performed as described above in Example 2. The PCR products were analyzed and

compared with a dilution series to estimate the percent of deletion present. As shown in Figure 13, approximately 0.04% of the alleles present showed evidence of the deletion.

[0204] The junction across the joined sections was sequenced and results are shown in Figure 14. Line 6 shows the genomic reference sequence at the target site of ZFN 15873 upstream of DPB2 (with the ZFN binding site itself underlined). Line 5 shows the genomic reference sequence around the binding site of ZFN 15909 downstream of DRA (with the ZFN binding site itself underlined). Lines 1-4 show the sequence of 4 separate subclones of the PCR product as described above and demonstrate that both target sequences are present indicating that the two ends have joined at the ZFN cleavage sites following the deletion. Line 7 shows the consensus of the deletion products.

[0205] These results indicate that large deletions (approximately 700Kb) can be made to delete portions of the HLA class II complex.

15

Example 5: ZFNs specific for HLA class II regulator genes

[0206] As described previously, the class II complex appears to be regulated by a master regulatory molecule CIITA. Thus, if the CIITA gene were disrupted or manipulated, it might be possible to disrupt or alter HLA class II expression as a whole. Thus, ZFN pairs were made to target the CIITA gene. Additionally, the RFX5 gene product appears to be part of the class II enhanceosome, and so disruption of this gene may also disrupt or alter HLA class II expression. Accordingly, ZFN pairs targeting this gene were made and tested as well. Both sets of ZFNs were tested using the Cel I assay as described above in K562 cells.

[0207] As shown in Figure 15, Cel I mismatch assay results show that the CIITA targeted ZFN pair (15486/15487) was able to cause gene modification in approximately 15% of the alleles, while the RFX5 targeted ZFN pair (15506/15507) caused gene modification in about 2% of the alleles. Control reactions include a mock transfection with no added DNA and a transfection using a GFP expression plasmid.

[0208] Next, the CIITA targeted ZFN pairs were tested by transfecting into RAJI cells. These cells are a lymphoblastoid cell line that is known to express HLA class II.

[0209] The gel depicted in Figure 16 shows a comparison of the Cel I activity in K562 cells alongside RAJI cells. 'K' depicts the results in K562 cells and 'R' depicts the results in RAJI cells. 'n.c.' depicts the negative control in cells without any added ZFN DNA during transfection. The results demonstrate that in K562 cells, 5 there was approximately 12-15% gene modification activity observed and in RAJI cells, approximately 1% probably reflecting the poorer transfection efficiency in RAJI cells.

10 **Example 6: Use of HLA knock out cells in combination with another genetic modification**

[0210] The CD19 marker is a cell surface marker that is expressed on 95% of all B-cell malignancies. It is not expressed on hematopoietic stem cells, or on normal tissues outside the B lineage; and is lost upon differentiation of B cells to mature plasma cells. Thus, CD19 represents an attractive target for targeted immunotherapy 15 for treatment of B cell lymphomas and B-ALL cells. T-cells containing a chimeric antigen receptor (CAR) specific for CD19 have been created (see Davies *et al* (2010) *Cancer Res* 70(10):3915-24) through transposon aided genomic insertion. Deletion of the HLA markers could allow such a cell therapy product to be used for a number of patients rather than just those with the matching HLA haplotype. Thus, the CAR-19 20 modified T cells were treated with the HLA A specific ZFNs as described above in Example 2. The cells were then analyzed by FACS analysis as described above.

[0211] As shown in Figure 17, analyzing the cells using a negative (isotype) control antibody (mouse anti-IgG2 (BD BioSciences)) showed a 0.3% negative (non-specific binding) signal for HLA-A2 (as described above) expression. When mock 25 transfected cells were analyzed with the HLA-A2 antibody (no mRNA), 1.6% of the cells did not express HLA-A2. A bulk population of T cells treated with ZFNs showed that 17.6 % of the cells were HLA A2 null, but following enrichment for HLA A2 non-expressers as described above in Example 2, 95.3% of the cells were HLA A2 null (compare "Enriched" with "HLA-A.ZFN bulk") in Figure 17.

30 [0212] The HLA A2 null T cells were then treated with HLA A2-specific CTLs. As is shown in Figure 18, the cells that were HLA A2 null were resistant to lysis by the CTLs. These experiments were carried out as described previously. The CTLs used were the GAS2B3-5 C19ORF48/A2 cells (CIPPDSLLFPA epitope) described previously (see Example 2) and are specific for HLA A2 .

[0213] These data demonstrate that ZFP mediated HLA knockouts can be made in cells that carry another useful genetic modification and thus allow a wider use of these therapeutics.

5 **Example 7: TCR knock out**

[0214] Use of the CAR-19 modified T cells as described above in Example 6 could be potentially hampered in an allogenic setting due to endogenous TCR $\alpha\beta$ expression. Thus, ZFN reagents designed to disrupt either the TCR α or the TCR β constant chains were tested in primary T cells. The ZFN pair 25539/25540 was used 10 for the TCR α knockout and the ZFN pair 16783/16787 was used for the TCR β knockout. In these experiments, 1 million primary T cells were subjected to nucleofection with the Amaxa system using the ZFN encoding mRNAs as described above. Cells were then subjected to both FACs and Cel I analyses.

[0215] As shown in Figure 19, cells lacking CD3 expression increase from 15 2.4%, without any nucleofected TCR ZFN mRNAs, to 9.4% in the presence of 10 μ g TCR β -specific ZFN mRNA. In the presence of 10 μ g TCR α -specific ZNF mRNA, the percent of CD3 negative cells increases to 28.1%. The FACs data is presented with the TRC β data is shown across the top ("TRBC target ZFNs") and the TCR α data is across the bottom ("TRAC target ZFNs"). Lack of expression of either the 20 TCR α or the TCR β chains is assayed by the presence of the CD3 complex, in which a functioning TCR is required for stable presentation on the cell surface.

[0216] Figure 20 depicts a gel with the results of the Cel I analysis, performed as described above on samples incubated under the transient hypothermic or the standard conditions, and the percent gene modification activity data (displayed at the 25 bottom of each lane) agrees roughly with the FACs analysis that was done on cells incubated at 37 degrees.

[0217] Although disclosure has been provided in some detail by way of illustration and example for the purposes of clarity of understanding, it will be apparent to those skilled in the art that various changes and modifications can be 30 practiced without departing from the scope of the disclosure. Accordingly, the foregoing descriptions and examples should not be construed as limiting.

CLAIMS

1. An isolated polypeptide comprising a non-naturally occurring zinc finger protein, wherein the zinc-finger protein comprises four, five or six zinc finger DNA recognition regions designated and ordered F1 to F4, F1 to F5 or F1 to F6 from N-terminus to C-terminus and further wherein the zinc finger protein comprises the zinc finger DNA recognition regions selected from the group consisting of:
 - (i) F1: QSSHLTR (SEQ ID NO:1);
F2: RSDHLTT (SEQ ID NO:2);
F3: RSDTLSQ (SEQ ID NO:3);
F4: RSADLSR (SEQ ID NO:4);
F5: QSSDLSR (SEQ ID NO:5); and
F6: RSDALTQ (SEQ ID NO:6), wherein the protein binds to the target site set forth in SEQ ID NO:97 in an endogenous HLA class 1 gene;
 - (ii) F1: QKTHLAK (SEQ ID NO:7);
F2: RSDTLSN (SEQ ID NO:8);
F3: RKDVRIT (SEQ ID NO:9);
F4: RSDHLST (SEQ ID NO:10); and
F5: DSSARKK (SEQ ID NO:11), wherein the protein binds to the target site set forth in SEQ ID NO:98 in an endogenous HLA class 1 gene;
 - (iii) F1: QNAHRKT (SEQ ID NO:12);
F2: RSDSLLR (SEQ ID NO:13);
F3: RNDDRKK (SEQ ID NO:14);
F4: RSDHLST (SEQ ID NO:10); and
F5: DSSARKK (SEQ ID NO:11), wherein the protein binds to the target site set forth in SEQ ID NO:99 in an endogenous HLA class 1 gene;
 - (iv) F1: DRSHLSR (SEQ ID NO:15);
F2: RSDDLTR (SEQ ID NO:16);
F3: DRSDLSR (SEQ ID NO:17); and
F4: QSGHLSR (SEQ ID NO:18), wherein the protein binds to the target site set forth in SEQ ID NO:100 in an endogenous HLA class 1 gene;
 - (v) F1: DRSALSR (SEQ ID NO:19);
F2: QSSDLRR (SEQ ID NO:20);
F3: DRSALSR (SEQ ID NO:19);

F4: DRSHLAR (SEQ ID NO:21);
F5: RSDDL SK (SEQ ID NO:22); and
F6: DRSHLAR (SEQ ID NO:21), wherein the protein binds to the target site set forth in SEQ ID NO:101 in an endogenous HLA class 1 gene;

5 (vi) F1: SSELLNE (SEQ ID NO:23);
F2: TSSHLSR (SEQ ID NO:24);
F3: QSGDRNK (SEQ ID NO:25);
F4: RSANLAR (SEQ ID NO:26); and
F5: RSDNLRE (SEQ ID NO:27), wherein the protein binds to the target site set forth in SEQ ID NO:102 in an endogenous HLA class 1 gene;

10 (vii) F1: QSGDLTR (SEQ ID NO:28);
F2: RSDDLTR (SEQ ID NO:16);
F3: DQSTLRN (SEQ ID NO:29);
F4: DRSNLSR (SEQ ID NO:30); and
F5: DAFTRTR (SEQ ID NO:31), wherein the protein binds to the target site set forth in SEQ ID NO:103 in an endogenous HLA class 1 gene;

15 (viii) F1: RSDNLSE (SEQ ID NO:32);
F2: ASKTRKN (SEQ ID NO:33);
F3: TSGNLTR (SEQ ID NO:34); and
F4: RSDALAR (SEQ ID NO:35), wherein the protein binds to the target site set forth in SEQ ID NO:104 in an endogenous HLA class 1 gene;

20 (ix) F1: DR SALS R (SEQ ID NO:19);
F2: QSGNLAR (SEQ ID NO:36);
F3: DR SALS R (SEQ ID NO:19); and
F4: QSGHLSR (SEQ ID NO:18), wherein the protein binds to the target site set forth in SEQ ID NO:105 in an endogenous HLA class 1 gene;

25 (x) F1: RSDNLSE (SEQ ID NO:32);
F2: ASKTRKN (SEQ ID NO:33);
F3: QSGHLSR (SEQ ID NO:18);
F4: TSGHLSR (SEQ ID NO:37); and
F5: QSGHLSR (SEQ ID NO:18), wherein the protein binds to the target site set forth in SEQ ID NO:106 in an endogenous HLA class 1 gene;

30 (xi) F1: RSADLTR (SEQ ID NO:38);
F2: QSGDLTR (SEQ ID NO:28);

F3: QSGNLAR (SEQ ID NO:36); and
F4: QSGDLTR (SEQ ID NO:28), wherein the protein binds to the
target site set forth in SEQ ID NO:107 in an endogenous HLA class 1 gene;

5 (xii) F1: QSGHLSR (SEQ ID NO:18);
F2: RSDHLST (SEQ ID NO:10);
F3: QSADRTK (SEQ ID NO:39);
F4: TSGSLSR (SEQ ID NO:40); and
F5: QSADRTK (SEQ ID NO:39), wherein the protein binds to the
target site set forth in SEQ ID NO:108 in an endogenous HLA class 1 gene;

10 10 (xiii) F1: QSGDLTR (SEQ ID NO:28);
F2: RSDHLST (SEQ ID NO:10);
F3: QSADRTK (SEQ ID NO:39);
F4: RSDNLSA (SEQ ID NO:41); and
F5: RSDNRTT (SEQ ID NO:42), wherein the protein binds to the
target site set forth in SEQ ID NO:109 in an endogenous HLA class 1 gene;

15 15 (xiv) F1: QRSNLVR (SEQ ID NO:43);
F2: DRSLALAR (SEQ ID NO:44);
F3: QSSDLRR (SEQ ID NO:20);
F4: RSDDLTR (SEQ ID NO:16); and
F5: RSDDLTR (SEQ ID NO:16), wherein the protein binds to the
target site set forth in SEQ ID NO:110 in an endogenous HLA class 1 gene; and

20 20 (xv) F1: RSDDLTR (SEQ ID NO:16);
F2: DRSDLRSR (SEQ ID NO:17);
F3: QSGHLSR (SEQ ID NO:18);
F4: RSDHLSA (SEQ ID NO:45); and
F5: ESRYLMV (SEQ ID NO:46), wherein the protein binds to the
target site set forth in SEQ ID NO:111 in an endogenous HLA class 1 gene.

2. A fusion protein comprising the isolated polypeptide of claim 1 and a
30 functional domain.

3. The fusion protein of claim 2, wherein the functional domain
comprises an activation domain, a repression domain or a nuclease domain.

4. The fusion protein of claim 2 or claim 3, wherein the functional domain modulates expression of one or more of an HLA A, HLA B, and HLA C genes.

5 5. An isolated cell comprising a polypeptide or fusion protein according to any one of claims 1 to 4.

6. An isolated cell comprising the polypeptide of claim 1 or the fusion protein according to any one of claims 2 to 4 or a polynucleotide that encodes the 10 polypeptide of claim 1 or the fusion protein as defined in any one of claims 2 to 4.

7. The isolated cell of claim 6, wherein the cell is selected from the group consisting of a stem cell, a progenitor cell, a T-cell or a Natural Killer (NK) cell, a partially differentiated progeny cell of the stem cell or a fully differentiated progeny 15 of the stem cell.

8. An *in vitro* method of inactivating one or more HLA class I genes in a cell, the method comprising:

20 cleaving the HLA class I genes with the fusion protein according to claim 3 or a polynucleotide that encodes the fusion protein of claim 3, wherein the functional domain comprises a nuclease such that the one or more HLA class I genes are inactivated.

9. The method of claim 8, wherein the cleavage results in a deletion 25 within one or more HLA class I genes.

10. An isolated cell for use to treat or to prevent an HLA related disorder in a subject, wherein the isolated cell is produced by the method of claim 8.

30 11. The isolated cell for use according to claim 10, wherein the isolated cell further comprises an additional genomic modification selected from the group consisting of integration of an exogenous sequence into the genome of the cell, inactivation of one or more additional genes, and combinations thereof.

12. The isolated cell for use according to claim 11, wherein the additional genomic modification comprises integration of an exogenous sequence and further wherein the exogenous sequence is integrated into the cleaved HLA class I gene.

5 13. The isolated cell for use according to claim 11 or 12, wherein the additional genomic modification comprises integration of an exogenous sequence and further wherein the exogenous sequence encodes a chimeric antigen receptor (CAR) specific for a cancer marker.

10 14. The isolated cell for use according to any one of claims 11 to 13, wherein the additional genomic modification comprises inactivation of one or more endogenous TCR genes.

15 15. The isolated cell for use according to any one of claims 11 to 14, wherein the disorder is graft-versus-host diseases (GVHD).

16. The isolated cell for use according to any one of claims 10 to 15, wherein the polynucleotide is mRNA or DNA.

20 17. The isolated cell for use according to claim 16, wherein the cell is a T-cell or a non-totipotent stem cell.

18. The isolated cell for use according to claim 17, wherein the stem cell is selected from the group consisting of an induced pluripotent stem cell (iPSC), a 25 human embryonic stem cell (hES), a mesenchymal stem cell (MSC) or a neuronal stem cell.

19. A cell line contained in a model system in which one or more HLA class I genes of the cell line are inactivated according to the method of claim 8 or 30 claim 9.

20. An isolated cell transplant for use to treat a patient in need of said cell transplant, wherein the transplant comprises

isolated cells in which one or more HLA class I genes have been inactivated, the isolated cells produced according to the method of claim 8 or 9; and
wherein the cells or fragments of the cells are in a form that is transplantable.

5 21. The cell transplant of claim 20, wherein the cells or cell fragments are selected from the group consisting of T-cells, non-totipotent stem cells and platelets.

22. Use of an isolated cell to treat or to prevent an HLA related disorder in a subject, wherein the isolated cell is produced by the method of claim 8.

10 23. The use of the isolated cell according to claim 22, wherein the isolated cell further comprises an additional genomic modification selected from the group consisting of integration of an exogenous sequence into the genome of the cell, inactivation of one or more additional genes, and combinations thereof.

15 24. The use of the isolated cell according to claim 23, wherein the additional genomic modification comprises integration of an exogenous sequence and further wherein the exogenous sequence is integrated into the cleaved HLA class I gene.

20 25. The use of the isolated cell according to claim 23 or 24, wherein the additional genomic modification comprises integration of an exogenous sequence and further wherein the exogenous sequence encodes a chimeric antigen receptor (CAR) specific for a cancer marker.

25 26. The use of the isolated cell according to any one of claims 23 to 25, wherein the additional genomic modification comprises inactivation of one or more endogenous TCR genes.

30 27. The use of the isolated cell according to any one of claims 23 to 26, wherein the disorder is graft-versus-host diseases (GVHD).

28. The use of the isolated cell according to any one of claims 22 to 27, wherein the polynucleotide is mRNA or DNA.

29. The use of the isolated cell according to claim 28, wherein the cell is a T-cell or a non-totipotent stem cell.


30. The use of the isolated cell according to claim 29, wherein the stem cell is selected from the group consisting of an induced pluripotent stem cell (iPSC), a human embryonic stem cell (hES), a mesenchymal stem cell (MSC) and a neuronal stem cell.

31. Use of a cell line to produce a model system in which one or more HLA class I genes of the cell line are inactivated according to the method of claim 8 or claim 9.

32. Use of an isolated cell transplant to treat a patient in need of said cell transplant, wherein the cell transplant comprises
15 isolated cells in which one or more HLA class I genes have been inactivated, the isolated cells produced according to the method of claim 8 or 9; and wherein the cells or fragments of the cells are in a form that is transplantable.

33. Use of the cell transplant of claim 32, wherein the cells or cell
20 fragments are selected from the group consisting of T-cells, non-totipotent stem cells and platelets.

1/20

**FIG. 1**

HLA Class I and Class II gene clusters

2/20






FIG. 2

3/20


**FIG. 3**

4/20



CTL Clone, 7A7 PANE1/A3
 Epitope: RVWDLPGVLK (SEQ
 ID NO:135)

FIG. 4A



CTL Clone, GAS2B3-5 C19ORF48/A2
 Epitope: CIPPDSLLFPA (SEQ ID NO:136)

FIG. 4B

5/20




FIG. 5A






FIG. 5B

6/20


FIG. 6



7/20

25588
25589

HLA C

25316
25317


HLA B

FIG. 7A**FIG. 7B**


8/20

FIG. 8A


HLA C-down

**FIG. 8B**


HLA B-up



9/20


Analysis**FIG. 9A**

15267+15265 / 15298+15296


**FIG. 9B**

10/20

TAP1

28386
28385 GFP

TAP2

28394
28393 GFP**FIG. 10A****FIG. 10B**

11/20


FIG. 11

Tapasin


28404/28403

28406/28405

GFP



12/20

FIG. 12**DPB2up****DRAdown**

13/20





FIG. 13

14/20


FIG. 14

15/20

FIG. 15




16/20


FIG. 16

R = RAJI cells
K = K562 cells

17/20

**FIG. 17**

18/20

**FIG. 18**

19/20





FIG. 19

FIG. 20ATRAC**FIG. 20B**



HLA Class I and Class II gene clusters